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Abstract 
Ras signaling activates multiple pathways that drive cell growth, proliferation, survival, 
and differentiation. Ras is activated downstream of multiple receptors by the recruitment and 
interaction with Ras guanine nucleotide exchange factors (RasGEFs). Efficient regulation of this 
signaling is essential for the avoidance of developmental defects and cancer, and cessation of 
Ras signaling is dependent on the recruitment of Ras GTPase activating proteins (RasGAPs) for 
juxtaposition with Ras. RasGAPs physically interact with Ras to allow for Ras hydrolization of 
bound GTP.  There are multiple RasGAPs, which have varied tissue expression patterns. The 
RasGAP p120 RasGAP (RASA1) has been shown to be important in the mouse embryonic 
cardiovasculature and adult lymphatic system. However, RASA1 has other roles than regulation 
of Ras, including interactions with p190 RhoGAP for directed cell migration. To address this, we 
generated a mouse carrying a point mutation in its GAP domain that ablates its GAP activity 
while retaining all other functions. With the use of these mice we show that it is the loss of 
RASA1’s ability to regulate Ras that results in failed cardiovascular development in embryos 
and the instability and outgrowth of lymphatic vessels in adult mice. 
Although RASA1 plays an important role in many tissues, it has a minor role in the 
regulation of Ras during T cell development.  Another RasGAP, Neurofibromin 1 (NF1) also 
appears to have a largely dispensable function in the T cell compartment.  Since loss of both 
RASA1 and NF1 in developing embryos results in earlier embryonic lethality than loss of either 
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RasGAP alone, we hypothesized that these RasGAPs may have overlapping functions in T cells.  
Indeed, concurrent deletion of RASA1 and NF1 in the T cell compartment resulted in in a 
randomly occurring T cell acute lymphoblastic leukemia (T-ALL) in mice associated with 
acquisition of somatic activating mutations in the Notch1 receptor previously implicated in T-
ALL pathogenesis. 
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Chapter 1 
Introduction 
 
1.1 Ras and Ras Signaling 
Ras is a small, inner membrane-bound G protein that plays a vital role in many important 
cellular functions, including cell growth, differentiation, proliferation, and survival [1]. Ras 
functions downstream of many cell surface receptors including cytokine receptors, growth factor 
receptors, and the T cell receptor (TCR). Ras acts as a molecular ‘on-off’ switch, converting 
between active and inactive states. Until it is activated, Ras exists in a GDP-bound inactive state. 
During receptor signaling, Ras guanine nucleotide exchange factors (RasGEFs) are recruited to 
membranes where they become juxtaposed to Ras [2]. RasGEFs interact with Ras to allow for 
the ejection of the GDP. Since GTP exists at a higher concentration within the cell cytosol than 
GDP, Ras then preferentially binds GTP and switches to an active conformation that triggers 
multiple downstream signaling pathways.   
 One of the signal transduction pathways Ras activates is the mitogen-activated protein 
kinase (MAPK) pathway (Figure 1).  GTP-bound Ras binds and activates the serine/threonine 
kinase Raf1, which phosphorylates two MAPK kinases, MEK1 and 2 [3]. MEK1/2 
phosphorylate the MAPK extracellular signal-regulated kinases 1 and 2 (ERK1/2), resulting in 
their activation and translocation to the cell nucleus. Within the nucleus ERK1/2 then 
phosphorylate members of the ternary complex factor (TCF) family of transcription factors, 
including Elk1, Sap1a and Sap1b, and Net [4].  The TCFs interact with serum response factor 
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(SFC) to bind specific sites in promoters of early response genes. This results in increased 
transcriptions of these genes, which include c-Fos. C-Fos and c-Jun are transcription factors that 
heterodimerize to form the transcription factor complex activation protein 1 (AP-1). ERK1/2 also 
phosphorylate both c-Fos and c-Jun, resulting in a stabilized c-Fos and increased transcriptional 
activity [5].  Through late activating genes, the MAPK pathway drives cell proliferation, along 
with other interactions with proteins that drive DNA synthesis and cell cycle progression [6].  
 
Figure 1. Activation and regulation of intracellular Ras signaling. Ras signaling occurs 
downstream of various receptors, including growth factor receptors. Activation of the receptors by 
their binding to specific ligands results tyrosine phosphorylation of the receptor leading to the 
recruitment of RasGEFs. RasGEF allows inactive GDP-bound Ras to eject the GDP and bind GTP 
and initiate signaling through multiple pathways, including the MAPK and PI3K/AKT pathways.  
RasGAPs are then recruited for efficient cessation of signaling by aiding in the hydrolyzation of 
Ras-bound GTP. 
 
 Ras also signals through the phosphatidylinositol 3-kinase (PI3K) pathway (Figure 1). 
GTP-bound Ras activates the catalytic subunit of PI3K (p110) independently from the p85 
subunit and phosphorylates phosphatidylinositol (4,5)-bisphosphate (PIP2) into 
phosphatidylinositol (3,4,5)-trisphosphate (PIP3) [7, 8]. PIP3 binds AKT and phosphoinositide-
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dependent kinase-1 (PDK1) by their pleckstrin homology (PH) domains, and brings both 
proteins to the cellular membrane. PDK1 phosphorylates AKT on Thr308, resulting in activation 
of AKT that leads to inhibition of the pro-apoptotic BAX and BAD along with negative 
regulation of NF-κB. AKT can also phosphorylate the tuberous sclerosis complex 2 (TSC2) 
complex, which allows for mammalian target of rapamycin complex 1 (mTORC1) signaling. 
mTORC1 signaling leads to increased p70S6 kinase activity, which stimulates protein 
biosynthesis [7, 8]. Mammalian target of rapamycin complex 2 (mTORC2) phosphorylates AKT 
on Ser473, and this phosphorylation is required for full activation of the protein  [9]. 
  
1.2 Regulation of Ras Signaling 
Although Ras has some intrinsic GTPase activity, Ras GTPase activating proteins 
(RasGAPs) are required for efficient GTP hydrolysis. RasGAPs increase Ras GTP hydrolysis by 
several orders of magnitude [2]. This occurs by the insertion of the RasGAP arginine finger 
(Arginine 789 in humans, 780 in mice) into the active site of Ras [10]. RasGAPs stabilize the 
switch II region of Ras, which allows Glutamine 61 (in humans) to carry out catalysis [11].  Also 
important in maintaining the interaction between Ras and RasGAPs are Glycines 12 and 13, 
mutations of which lead to impaired interactions between RasGAP Arg789 and Ras Glu61. 
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Figure 2. The domain structures of RasGAPs [12]. 
The RasGAP family currently has ten known members, each of which contain a GAP 
domain that is required for interaction with and inactivation of Ras (Figure 2) [12].  This  
approximately 330 amino acid catalytic domain is the only common domain shared between all 
family members [10]. The RasGAPs contain other domains, including Src homology 2 (SH2) 
and SH3, PH, protein kinase C2, Bruton tyrosine kinase (BTK), and SEC14-PH domains [12].  
These domains are often involved in the recruitment of the RasGAPs to membranes for 
juxtaposition with Ras or can act as the basis for the organization of protein complexes [2]. 
While identified as RasGAPs, these proteins may also have Ras-independent functions [10]. 
RasGAPs have variable expression patterns. Some RasGAPs, including p120 RasGAP, 
Neurofibromin 1,  RASA2, DAB2ip, and RASAL2 are expressed ubiquitously, while other 
RasGAPs are more limited in expression [12]. For example, SynGAP is expressed in neurons 
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while RASA3 is localized to the brain and spleen.  Thus it is likely that any given tissue 
expresses multiple RasGAPs. 
 
1.3 Cancer and Rasopathies 
Because of the breadth of cellular processes that are under the control of Ras, Ras 
activation is tightly regulated by RasGAPs. However, mutations in Ras occur that affect the 
structure of Ras such that RasGAPs are unable to stabilize the switch regions.  This includes 
mutations of Gly12 and 13 and Glu61[13].   These mutations result in constitutively active Ras 
signaling [11]. Ras mutations occur in approximately 30% of all human cancers, with a higher 
incidence in pancreatic, colon, lung and thyroid cancers, and in hematological malignancies such 
as myeloid leukemias and T and B cell lymphoma/leukemias  [13].  In order to study the role of 
Ras mutations in cancer, mouse models have been generated to express constitutively active Ras 
carrying similar mutations to those found in cancer patients through induction of Cre transgene 
expression [14]. When induced in the hematopoietic compartment, the activating K-rasG12D 
mutation results in all mice developing a lethal myeloproliferative disorder [15].  Transferring K-
rasG12D expressing bone marrow into wild type mice results in the majority of recipients 
developing a T-cell leukemia/lymphoma carrying mutations in additional genes [16].   
Germline mutations that cause perturbations in Ras signaling, particularly through the 
MAPK pathway, can result in a variety of disorders collectively called Rasopathies. These 
include Noonan syndrome, Costello syndrome, Noonan syndrome with multiple lentigines 
(NSML, formerly known as LEOPARD syndrome), cardio-facial-cutaneous syndrome, Legius 
syndrome, neurofibromatosis type 1, and cardiovascular malformation-arteriovenous 
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malformation (CM-AVM) [17].  These developmental disorders share some characteristic 
phenotypes including cardiac malformations, aberrant craniofacial morphology, varying levels of 
cognitive impairment and delay, along with malformations in other systems [18].  Not 
surprisingly, some of these disorders are associated with an increased risk of cancer. 
 
Syndrome Ras/MAPK 
pathway gene 
Protein Protein function 
Capillary malformation-
arteriovenous 
malformation 
 
RASA1 p120 RasGAP (RASA1) RasGAP 
Cardio-facial-cutaneous 
Syndrome 
 
 
 
BRAF 
MAP2K1 
MAP2K2 
KRAS 
BRAF 
MEK1 
MEK2 
KRAS 
Kinase 
Kinase 
Kinase 
GTPase 
Costello Syndrome 
 
HRAS HRAS GTPase 
Legius Syndrome SPRED1 SPRED1 SPROUTY-
related, EVH1 
domain-containing 
protein 
Neurofibromatosis 1 
 
NF1 Neurofibromin (NF1) RasGAP 
Noonan Syndrome PTPN11 
SOS1 
RAF1 
KRAS 
NRAS 
SHOC2 
CBL 
SHP2 
SOS1 
CRAF 
KRAS 
NRAS 
SHOC2 
CBL 
Phosphatase 
RasGEF 
Kinase 
GTPase 
GTPase 
Scaffolding 
E3 ubiquitin ligase 
 
Noonan Syndrome with 
multiple lentigines 
PTPN11 
RAF1 
SHP2 
RAF1/CRAF 
Phosphatase 
Kinase 
Table 1.  List of Rasopathies with associated genes, their encoded proteins, and protein 
functions [17]. 
 
1.4 T Cell Development 
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 T cells undergo a multistep developmental process, originating from hematopoietic stem 
cells in the bone marrow which traffic to the thymus [19].  The thymus consists of multiple 
lobes, each containing medullary and cortical regions, through which thymocytes pass as they 
develop.  Early thymocyte progenitors (ETPs) are the first cells to seed the thymus [20].  
Although ETPs are generally considered to be equivalent to double negative 1 (DN) cells, which 
do not yet express the T cell co-receptors CD4 or CD8, ETPs often have low CD4 expression 
[21, 22]. DN cells continue from stages 1 to 4, identified by changing expression of CD44 and 
CD25 (DN1 CD44+CD25-; DN2 CD44+CD25+; DN3 CD44-CD25+; DN4 CD44-CD25-) [23]. 
At the DN2-DN3 transition, the TCRβ chain gene undergoes rearrangement, resulting in the 
expression of the pre-TCR at DN3.  At this point, signaling through the pre-TCR is essential for 
thymocyte survival and progression to DN4 [24]. 
 In response to pre-TCR signaling, thymocytes undergo a proliferative burst and start 
expressing the CD4 and CD8 co-receptors (double positive, DP). DP cells undergo TCRα gene 
rearrangement which if successful results in expression of the TCRαβ receptor at the cell surface. 
At this stage, the TCR expressing DP cells undergo a process known as positive selection, in 
which the newly formed TCRαβ are tested for their ability to recognize self-MHC when bound to 
self-peptide. TCR recognition of the MHC-bound peptide complex at this stage results in cell 
survival. The strength of the interaction determines whether the cells commit to either the CD4 
or CD8 lineage, and results in the loss of the other co-receptor [25]. 
After cells that can recognize self MHC stop proliferating, they go through a process 
known as negative selection. Signal strength from interaction with MCH with self-peptides 
determines the fate of the developing thymocyte [26].  Cells that do not receive enough signal 
die by neglect [27]. However, cells that have a strong affinity for self-antigen cannot be released 
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into the periphery as this could result in autoimmunity.  Thus, those that react strongly to various 
self-antigens are deleted [28].  
 Ras signaling has been shown to be essential for thymocyte development.  ERK 
downstream of MEK1 is required for the differentiation of DN3 thymocytes [29]. ERK1/2 
downstream of Ras is also important for positive selection. TCRβ development in mice deficient 
in both ERK1 and 2 is nearly completely blocked at this stage [30, 31] Further on in 
development, constitutive expression of ERK2 leads to a preferential development of DP 
thymocytes to CD4 cells [32].  Ras signaling during positive selection may be driven by the 
RasGEF RasGRP1 [33, 34], however negative regulation of Ras throughout thymocyte 
development is not well understood. Similarly, Ras activation downstream of the TCR is known 
to be driven by the RasGEFs Sos and RasGRP1 [35, 36], while the RasGAP or GAPs that act to 
regulate this signaling are unknown. 
 
1.5 Physiological Functions of p120 RasGAP 
 The first described RasGAP family member was p120 RasGAP (RASA1), which along 
with a GAP domain contains SH2, SH3, PH, and protein kinase C2 domains [2].  Mice that are 
homozygous null for Rasa1 die in utero at embryonic day 10.5 (E10.5) due to aberrant blood 
vessel development [37]. At E9.5 RASA1 null embryos showed failed vascular organization in 
the yolk sac along with a thinner dorsal aorta with aberrant intersegmental artery branching in 
the embryo proper.   Interestingly, although RASA1 is ubiquitously expressed, adult mice that 
have induced loss of RASA1 in all tissues have no identifiable spontaneous cardiovascular 
phenotype [38], although loss of RASA1 may result in increased angiogenesis under certain 
experimental conditions [39].  Specific deletion of RASA1 in the T cell compartment during T 
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cell development leads to a slight increase in thymocyte positive selection in the thymus and 
reduced numbers of naïve cells in the periphery [40]. However, the increase in positive selection 
is apparent only on TCR transgene backgrounds. This suggests that other RasGAPs are more 
important in regulation of T cell development and function and cardiovascular maintenance. 
Alternatively, other RasGAPs have overlapping functions with RASA1 in these systems. 
 
 
Figure 3. Lymphatic and cardiovascular systems [41]. 
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 Although RASA1 is not necessary for cardiovascular maintenance, adult mice with 
induced loss of RASA1 develop a striking lymphatic system hyperplasia and leakage [38]. The 
lymphatic system is essential for the uptake of interstitial fluid, macromolecules and trafficking 
of immune cells, and returns them to the bloodstream [42]. Lymphatic capillaries are composed 
of oak leaf shaped endothelial cells (LEC) that form button-like junctions with overlapping edges 
that result in valve-like openings (Figure 3) [41]. Entrance of fluid is possible as lymphatic 
capillaries lack basement membrane and maintain structural integrity via anchoring filaments 
[43]. These capillaries feed into larger pre-collecting lymphatics, which have basement 
membrane and have characteristics of both capillaries and collecting vessels. Collecting vessels 
also have basement membrane, and are surrounded by vascular smooth muscle cells (SMC) [41]. 
SMC cells have contractile activity that drives lymph flow, and precollecting and collecting 
lymphatic vessels have valve cells to maintain the unidirectional flow of lymph. LEC in 
collecting vessels form zipper-like junctions, composed of the same tight and adherens junction 
associated proteins (such as VE-cadherin) as the button-like junctions of lymphatic vessels, but 
in a different arrangement (Figure 4) [44].  
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Figure 4. Junctional organization of LEC in lymphatic capillaries and collecting vessels 
[43]. Both types of junctions are composed of tight- and adherens junction associated proteins, 
but have different organization.  
 
 Lymph sacs containing LEC develop off of the cardinal and iliac veins, and these cells 
are the progenitors of the entire lymphatic vasculature [45]. The homeobox transcription factor 
Prox1 that specifies LEC fate is detectable in mice at starting at E9.5. Lymphatic endothelial 
hyaluronan receptor-1 (LYVE-1) is expressed at E9, making it the first identifier of lymphatic 
cell fate, although it does not seem essential for lymphatic vessel development [41]. Vascular 
endothelial growth factor C (VEGF-C) signaling through vascular endothelial growth factor 
receptor 3 (VEGFR3) is essential for lymphatic development and maintenance, as loss of Vegfc 
in embryos results in complete lack of lymphatic vasculature [46]. VEGFR3 signaling is also 
important in mature lymphatic vessels, as blockade of VEGFR3 results in impaired lymphatic 
vessel regeneration [47]. Similarly, overexpression of VEGF-C in embryos results in them 
developing chylothorax, where lymphatic fluid fills the thoracic cavity [48]. 
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 Perturbations in lymphatic vessel maintenance and structure in humans can give rise to 
different disorders. Loss of uptake by the lymphatic vessels results in accumulation of interstitial 
fluid and proteins, eventually resulting in lymphedema, which is a chronic progressive swelling 
[41]. Primary lymphedema is caused by genetic mutations, including some of the Rasopathies 
[49]. Secondary lymphedema arises after some trauma to the lymphatic vasculature, such as after 
mastectomy [41]. The most common form of secondary lymphedema is filariasis, which is a 
nematode infection of the lymphatic system that results in lymphatic vessel dilation and 
blockage. Treatment options for lymphedema patients are mostly limited to ameliorating the 
symptoms, and current options are not very effective.  
In RASA1 deficient adult mice, the lymphatic system undergoes extensive growth and 
dilation, as the lymphatic endothelial cells (LEC) have significantly increased proliferation [38].  
The lymphatic system is also leaky, resulting in chylous ascites and chylothorax, from which the 
mice succumb.  This phenotype is recapitulated when RASA1 is specifically deleted in LEC, 
suggesting that the lymphatic disorder is intrinsic to these cells. Stimulation of RASA1 deficient 
LEC with the growth factor VEGF-C results in aberrant Ras signaling through the LEC 
expressed receptor VEGFR-3, which is the major pathway involved in the development of the 
lymphatic phenotype [38].  
 Mutations in RASA1 in humans also affect the cardiovascular and lymphatic systems. 
Humans with heterozygous, germline mutations in RASA1 develop the disease capillary 
malformation-arteriovenous malformation (CM-AVM) with a high percentage of penetrance 
[50].  CM-AVM is characterized by multifocal, randomly distributed skin CM, with 
approximately one third of patients also displaying fast flow vascular lesions [51]. These fast 
flow lesions can include AVM and arteriovenous fistulas which can occur intracranially, and 
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Parkes Weber syndrome, which often presents with an outgrowth of the affected extremity [52]. 
It is believed that complete loss of protein occurs through second hit mutations, which is 
consistent with the multifocal nature and range in severity of the disorder. Due to the lymphatic 
phenotype developed by the Rasa1 deficient adult mouse, human CM-AVM patients were 
screened and were shown to present with lymphatic system malformations [53].  Treatment 
options for these patients are limited and generally focus on alleviating symptoms, thus a better 
understanding of the downstream effects of loss of RASA1 would be beneficial in elucidating the 
most effective course of treatment. 
 
1.6 Ras Independent Functions of RASA1 
 While originally identified as a RasGAP, RASA1 has been shown to interact with other 
proteins during cellular signal transduction, in addition to Ras.  RASA1 interacts with p190 
RhoGAP, a RhoGTPase activating protein (RhoGAP), via its SH2 domains [54]. Rho, a member 
of the Ras GTPase superfamily, is a molecular switch protein that is known to regulate the actin 
cytoskeleton [55]. Loss of RASA1 in murine embryonic fibroblasts (MEF) results in reduced 
levels of tyrosine phosphorylation of p190 RhoGAP both in resting cells and after stimulation 
with platelet-derived growth factor (PDGF) [56].  RASA1 interactions with p190 RhoGap have 
been shown to be involved in regulating stress fiber and actin filament remodeling in directed 
cell migration [55]. Loss of RASA1 results in lack of cell polarization during wound healing 
which can be rescued by a RASA1 protein lacking the GAP domain. RASA1 also interacts with 
deleted in liver cancer 1 (DLC1), a RhoGAP via its SH3 domain [57]. Overexpression of 
RASA1 in a RasGAP-insensitive cancer cell line results in increased RhoA activity, and 
adenovirus driven expression of RASA1 in carcinoma cells expressing DLC1 results in increased 
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cell proliferation. Clearly RASA1 has multiple different roles, and loss of the entire protein can 
disrupt multiple different pathways controlling various cellular processes. 
 
1.7 Neurofibromin 1 
 Along with RASA1, other RasGAPs are also ubiquitously expressed. The overlap in 
expression of multiple RasGAPs suggests that there may be redundancy in RasGAP function. 
However, RasGAPs can have non-redundant roles in the same tissues. Another widely expressed 
RasGAP is Neurofibromin 1 (NF1), which contains a glycerophospholipid-binding SEC14-PH 
domain along with its GAP domain [12].  NF1 deficient mice die in utero around E13.5 due to 
abnormal heart development [58, 59].  Conditional deletion of NF1 in different tissues in mice 
results in the development of multiple phenotypes, including myeloid proliferation disorders [60-
62]. Mice that are deficient of NF1 in Schwann cells with NF1 haploinsufficient bone marrow 
develop complex tumors known as neurofibromas [61]. Loss of NF1 specifically in the T cell 
compartment results in a subtle phenotype similar to that of RASA1 [63]. Loss of NF1 results in 
a decrease in naïve peripheral T cells, and impaired positive selection in the thymus on a TCR 
transgenic background. The concurrent loss of both RASA1 and NF1 in mice results in arrested 
development earlier than loss of either RasGAP alone, as E9.0 Rasa1 and Nf1 deficient embryos 
have reduced somite numbers, lack of limb buds, and impaired heart and anterior structure 
formation [37]. 
  Germline NF1 mutations in humans result in the disease neurofibromatosis, which is 
characterized by plexiform neurofibromas on peripheral nerves [64]. Along with 
neurofibromatosis, children with mutations in NF1 are at risk of developing various myeloid 
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disorders including juvenile myelomonocytic leukemia (JMML) [65]. This myeloid disorder is 
less aggressive than that developed by induction of the activating Ras mutation in the 
hematopoietic compartment, but both types of mutations are found in patients with JMML, 
suggesting this cancer is due to aberrant Ras activation [15]. 
 
1.8 T Cell Acute Lymphoblastic Leukemia/Lymphoma 
 Wild type mice that receive bone marrow transplants from RasG12D mice succumb to T 
cell acute lymphoblastic leukemia/lymphoma (T-ALL) [16]. T-ALL accounts for 15% and 25% 
of childhood and adult ALLs, and requires aggressive treatment regimens that can be detrimental 
to the patients [66].  Ras mutations in human T-ALLs are relatively rare, however increased Ras 
signaling can be detected, suggesting that there are perturbations in the Ras signaling pathway 
[67].  Along with chromosomal translocations that result in gene fusions or deletions of tumor 
suppressing genes, the most common mutations in human T-ALL are activating gene mutations 
[68].  One of the most commonly mutated genes identified in T-ALL patients is NOTCH1, which 
is mutated in over 50% of cases [69].  These mutations result in gain of function of the NOTCH1 
protein. The T-ALL that develops in mice that receive K-rasG12D expressing bone marrow also 
carries Notch1 mutations [16]. 
 
1.9 Notch1 Mutations in T-ALL 
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Figure 5. Notch1 signaling pathway [70]. Notch1 recognition of ligands (Delta-like and 
Jagged) results in ADAM10 cleavage at the S2 site, followed by cleavage at the S3 site by γ-
secretase. The intercellular portion (ICN1) is released and translocates into the nucleus where it 
forms a complex with MAML1 and CSL to drive transcription of Notch1 target genes. 
 
 Notch1 is member of the Notch protein family, which consists of four transmembrane 
receptors that are involved in various aspects of cellular differentiation [71].  Notch1 is a 
heterodimer that has an extracellular domain which consists of epidermal growth factor (EGF) 
repeats which bind ligand, and LIN12/Notch repeats which block ligand-independent signaling 
[71, 72]. When Notch1 binds a ligand, which include Jagged and Delta-like ligands, it undergoes 
a metalloprotease-dependent cleavage at the S2 site near the transmembrane domain (Figure 5).  
Secondary cleavage within the transmembrane domain at S3 occurs by a multi-protein complex 
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with γ-secretase activity, resulting in an intracellular form of Notch1 (ICN).  The ICN consists of 
a RAM domain, nuclear localization sequences, ankyrin repeats, a transactivation domain, and a 
proline-glutamic acid-serine-threonine (PEST) domain.  The ICN translocates into the nucleus, 
where it interacts with the DNA-binding factor CSL and Mastermind-like (MAML) to form a 
complex that results in the expression of Notch1 target genes. 
 Notch1 signaling is required for normal development of T cells, as loss of Notch1 in 
common lymphoid progenitors results in the absence of T cells and the production of B cells in 
the thymus [73].  Loss of Notch1 during the DN2/DN3 stage of thymocyte development by use 
of conditional knockouts driven by pLCK-Cre results in aberrant DN3 and DN4 populations that 
do not undergo correct TCR rearrangement but still progress, although with reduced numbers of 
DP and a small thymus overall [74]. Interestingly, constitutive Notch1 signaling permits cells 
without TCRβ rearrangements to progress on to the DN4 stage, suggesting Notch1 signaling acts 
through the same pathways as the pre-TCR [75].  Clearly Notch1 signaling is important for 
correct T cell development and its expression must be tightly regulated. 
 Gain of function mutations in Notch1 can occur at multiple sites.  In human T-ALL, 
mutations often occur in exons 26 and 27, which encode the heterodimerization domain (HD) 
[69].  These mutations result in ligand-independent cleavage at S2, allowing for γ-secretase 
cleavage and release of ICN to drive constitutively active Notch1 signaling.  Mutations also 
occur in exon 34, which encodes the PEST domain.  Mutations in the PEST domain result in 
premature stop codons and the loss of a recognition sequence that prevents ICN from being 
targeted for ubiquitylation and thus extends the timing of Notch1 signaling [76]. These mutations 
can occur in the same T-ALL, often on the same chromosome [69].  However, these PEST 
mutations vary in strength, and are generally not sufficient to initiate T-ALL [77].  Instead, it has 
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been shown that these mutations are collaborative with other oncogenic mutations, such as Ras 
mutations. 
 PEST domain mutations also occur in mouse models of T-ALL, whereas mutations in the 
HD domain are rare [78]. Interestingly, mouse models of T-ALL often carry different types of 
mutations that result in ligand-independent cleavage of Notch1.  Type 1 mutations are 
recombination activating gene (RAG)-mediated recombinations that result in the excision of 
exons 1 and 2, while Type 2 mutations are RAG-independent deletions that lead to the loss of 
exon 2 through 25 or 26 [79, 80].  In both cases, translation starts at methionine 1727, which 
results in a membrane-bound form of Notch1 that can be cleaved by γ-secretase, resulting in 
constitutive ICN that is sufficient to drive T-ALL [79]. In all cases, these Notch1 mutations were 
identified in T-ALL that developed in mice carrying known genetic alterations of other genes, 
including K-rasG12D [78-80]. 
 
1.10 Generation of Genetically Altered Mice 
 Genetically altered mice provide opportunity to explore protein function in the context of 
the whole animal.  Traditionally, genetic targeting is achieved by homologous recombination in 
embryonic stem (ES) cells. Removal or replacement of exons is carried out by generating a 
targeting construct carrying the mutations, with homologous sequences flanking each end, along 
with an antibiotic resistance cassette such as Neomycin.  This construct is injected into ES cells, 
and homologous recombination results in the mutation integrating into the genome such that it 
replaces the endogenous exons, and does not insert randomly.  ES are grown on antibiotic-
containing media for selection of those expressing the targeted allele, and those are injected into 
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blastocysts and implanted into pseudo-pregnant females to generate chimeric mice.  The 
chimeras are crossed to wild type mice for germline expression of the targeted allele, resulting in 
mice with heterozygous expression of the mutated protein.  These mice are then crossed to 
generate homozygous mice that only express the targeted allele [81]. 
Since even partial loss of protein expression can often result in embryonic lethality, 
conditional knockout mice can be generated to allow the mouse to develop into adulthood, as 
well as to study the role of a protein in specific tissues.  Similar to the knockout mouse, a 
targeting vector is constructed, but exon(s) of interest are flanked by recombination site, such as 
loxP sites (floxed).  LoxP sites are specific sequences that are recognized by Cre recombinase, 
originally identified in bacteriophage P1 [82]. Cre recognition of loxP sites results in the 
recombination of the DNA between the sites, splicing out the floxed exons. Because loxP sites 
are only 34 bp, their insertion into introns does not usually affect normal gene expression, so 
floxed alleles typically express normal levels of functioning protein until Cre-mediated deletion 
occurs. Mice carrying a floxed allele are generated through the same process as the knockout 
mice, with the additional step of being crossed to transgenic mice carrying the Cre recombinase 
driven by tissue-specific and/or inducible promoters. Thus, the role of the protein in adult mice 
or in specific organ systems may be more easily elucidated. 
 RASA1 knockout mice were generated by the replacement of the exons encoding the N-
terminal SH2 domain with a neomycin resistance gene [37]. RASA1 conditional knockouts have 
been generated by placing loxP sites around exon 18, which encodes the part of GAP domain 
containing the arginine finger [83].  Loss of exon 18 results in the complete loss of the RASA1 
protein, presumably through nonsense mediated RNA decay.  Thus, it is unknown whether the 
phenotypes developed by either the null or the conditional knockout mice are due to loss of 
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RASA1’s regulation of Ras or some Ras-independent function.  Point mutations of RASA1’s 
arginine finger to a glutamine abrogates RASA1’s GAP activity while retaining the tertiary 
structure of the protein.  This amino acid substitution knocked in to a mouse would allow for the 
study of the role of RASA1’s Ras-targeted catalytic activity. 
 
1.11 Scope of the Thesis 
 There are two main questions addressed in this thesis. The first is to elucidate the role of 
RASA1’s GAP domain in cardiovascular development and lymphatic vessel maintenance.  By 
generating a knock-in mouse carrying an R780Q point mutation, we remove RASA1’s ability to 
regulate Ras while retaining all other functions of the protein.  In Chapter 2, generation of the 
Rasa1 R780Q knock-in mouse is detailed. In Chapter 3 this mouse is used to study the influence 
of the mutation upon the cardiovascular and lymphatic systems. The second question addressed 
in this thesis is the possibility that multiple RasGAPs are involved in regulation of Ras in T cell 
development. In Chapter 4, using mice that are floxed for both RASA1 and NF1 with the T cell 
specific LCK promoter driven Cre, we analyze the effects of the loss of these RasGAPs in the T 
cell compartment.  
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Chapter 2 
Generation of RASA1 R780Q knock-in mice 
2.1 Abstract 
 p120 RasGAP (RASA1) is a prototypical member of the RasGAP family that regulates 
Ras signaling downstream of various cell surface receptors.  Along with its GAP domain, 
RASA1 has multiple other domains through which it carries out Ras-independent functions. 
Aside from its function as a Ras regulator, RASA1 has been shown to interact with p190 
RhoGAP through its SH2 domain and DLC1 via its SH3 domain to regulate directed cell 
migration and Rho activation.  Mutations in humans result in the disease capillary malformation-
arteriovenous malformation (CM-AVM), which is characterized by small multifocal skin lesions 
as well as fast flow lesions along with lymphatic vessel issues. Similarly, RASA1 deficient mice 
die in utero due to failed cardiovascular system development whereas deletion of Rasa1 in adult 
mice leads to a lymphatic hyperplasia and leakage.   
 Since the RASA1 protein is entirely lost in these mouse models and is also thought to be 
lost in CM-AVM, it is unknown whether the phenotypes are due to loss of RASA1’s regulation 
of Ras or loss of a Ras-independent function.  This knowledge would be beneficial for 
identifying possible treatments for CM-AVM.  To address this, we have generated a knock-in 
mouse carrying a point mutation in its GAP domain that abrogates its ability to successfully 
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promote Ras hydrolysis of GTP.  This point mutation does not affect the tertiary structure of 
RASA1, such that the protein is competent to carry out other functions.  This RASA1 R780Q 
mouse can be used to address the importance of RASA1’s Ras directed catalytic activity in both 
the cardiovascular and lymphatic systems. 
2.2 Introduction  
 Ras is a small GTP binding protein that activates signaling downstream of a number of 
receptors, including growth factor receptors, cytokine receptors, and the TCR [1].  Binding of the 
receptor to its ligand results in the recruitment of RasGEFs, which allow Ras to bind GTP and 
become active.  Ras signaling is important in multiple cellular processes, including growth, 
differentiation, and survival.  Regulation of this signaling is critical for normal cell growth, 
proliferation and survival. For efficient cessation of  Ras signaling RasGAPs are recruited to 
interact with Ras, increasing its ability to hydrolyze GTP by several orders of magnitude [2]. 
 There are ten known RasGAP family members [12]. The first RasGAP identified was 
p120 RasGAP (RASA1).  Along with its GAP domain, through which it is able to stabilize Ras 
for efficient GTP hydrolysis, RASA1 has two SH2 domains as well as SH3, PH, and C2 
domains.  While these domains may be involved in recruitment of RASA1 to the membrane for 
juxtaposition with Ras, RASA1 has other known Ras-independent functions.  Via its SH2 
domain, RASA1 interacts with p190 RhoGAP [56].  This interaction is essential for directed cell 
movement of murine embryonic fibroblasts (MEFs) in vitro [55]. The loss of cell polarity in 
RASA1 deficient cells can be rescued by a RASA1 protein construct with no GAP domain, 
suggesting this interaction is Ras independent. RASA1 has also been shown to interact with 
DLC1, a RhoGAP, resulting in increased RhoA activation in a RasGAP resistant cell line and 
23 
 
increased cell proliferation [57].  This data indicates that through its modular binding domains, 
RASA1 has Ras independent functions. 
 The complete loss of RASA1 in mice results in an embryonic lethal phenotype at mid-
gestation [37]. The yolk sacs of these embryos fail to develop a correctly organized blood vessel 
network, instead the endothelial cells maintain a honeycomb like structure with no 
reorganization into vessels.  At the twelve somite stage the embryo proper has a thinner dorsal 
aorta than either wild type or heterozygous knockout littermates that are indistinguishable from 
one another in all respects.  The dorsal aorta also shows aberrant ventral branching, and there is 
often pericardial edema.  Interestingly, ubiquitous loss of RASA1 in adult mice does not result in 
the development of any spontaneous cardiovascular phenotypes [38].  Instead, the mice develop 
a severe lymphatic vessel hyperplasia, with an increased proliferation of LEC.  The lymphatic 
vasculature is also leaky, resulting in chylous ascites and lethal chylothorax.   
 Patients with the disorder CM-AVM have recently been found to carry RASA1 mutations 
[51].  CM-AVM is characterized by small, multifocal skin CM.  One third of patients also have 
fast flow lesions, including AVM, arteriovenous fistulas, and Parkes Weber syndrome.  Patients 
may also present with lymphatic abnormalities [53].  The mutations in humans span the length of 
the gene, and are believed to result in the loss of the entire protein [50, 52].  It is hypothesized 
that second hit mutations occur during development that result in the complete loss of RASA1.  
This theory is supported by the multifocal nature of the disorder as well as the range in severity 
of the disorder, which could be due to the timing of the mutation during development. 
 Since in both mouse and humans RASA1 phenotypes are consequent to complete loss of 
RASA1, it is uncertain whether these phenotypes are due to loss of Ras or Ras independent 
functions.  It has been shown previously that a point mutation in the GAP domain (R786Q) 
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would abrogate RASA1’s GAP activity by removing the arginine finger while not affecting the 
tertiary structure of the protein [84].  Therefore, we generated a R780Q knock-in mouse to 
address the importance of RASA1’s regulation of Ras in cardiovascular development and 
lymphatic system maintenance. 
 
2.3 Targeting Strategy and Construction of Knock-in Allele 
 The arginine finger of RASA1 is essential for the stabilization of Ras for efficient GTP 
hydrolysis. Mutation of the arginine in the arginine finger of RASA1 to a glutamine results in 
complete loss of GAP activity with no disruption of protein folding [84].  We designed a Rasa1 
targeting construct with a CGA to CAA codon change to generate the R780Q point mutation 
(Figure 6). The targeting construct carried a FRT-flanked Neomycin resistance cassette in intron 
18 for selection purposes. The FRT site is a recognized by the FLP recombinase originally 
identified in Saccharomyces cerevisiae and adapted for use in mammalian systems [85]. This 
construct was electroporated into W4 ES cells, which were cultured in neomycin.  DNA was 
isolated from growing cells and a quantitative PCR (qPCR) screen was used to distinguish 
correctly targeted ES cells from random integrants. 
 In order to identify correctly targeted ES cells, primer probe sets were designed which 
would allow identification of clones with one copy of the targeting construct that had been 
correctly integrated.  Taking advantage of the insertion of the Neomycin resistance cassette 
(NeoR), a primer probe set was generated that spanned the insertion site.  This results in the loss 
of amplification and probe binding in cells that have the NeoR cassette containing allele.  We 
calculated fold change and looked for a two-fold difference as compared to wild type genomic 
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DNA [86, 87].  The clones that had the correct fold change underwent a second qPCR where the 
primer probe set was located in exon 14, which was contained in the targeting construct, to 
eliminate clones with additional random integration on the targeting construct (Figure 7). 
 Correctly targeted clones were sequenced to confirm the presence of all exons and that 
the point mutation was present.  Two of the clones were injected into C57BL/6J X (C57BL/6J X 
DBA/2) blastocysts to generate chimeric mice.  Germline transmission was achieved by breeding 
to C57BL/6 actin promoter-driven Flp transgenic mice which removed the NeoR cassette[88].  
The resulting germline transmitted mice were crossed to C57BL/6J mice to confirm that deletion 
of the NeoR cassette was germline and not due to continued presence and activity of the Flp 
transgene.  Resulting heterozygous RASA1 R780Q mice were normal with no obvious 
phenotypes, similar to the RASA1 heterozygous null mice.  Heterozygous RASA1 R780Q mice 
were crossed with mice carrying conditional alleles of Rasa1 (fl) to generate Rasa1fl/R780Q mice. 
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Figure 6.  Targeting vector and homologously recombined correctly targeted allele. An 
R780Q targeting vector with an R780Q mutation in exon 18 and a FRT-flanked NeoR cassette in 
intron 18 is shown below the endogenous allele. In the middle is shown the R780Q targeted 
allele before and after excision of the NeoR cassette achieved with an actin promoter-driven Flp 
transgene (Act-Flp). At bottom is depicted a Rasa1 floxed allele in which exon 18 is flanked by 
loxP sites. Positions of real-time PCR primer/probe pairs used in the detection of ES cell 
homologous recombinants and PCR primer pairs used in mouse genotyping are indicated. C2, 
protein kinase C2 homology; GAP, GTPase-activating protein domain; PH, pleckstrin homology; 
SH2, Src homology 2; SH3, Src homology 3 
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Figure 7. qPCR screening of targeted ES cells. DNA was isolated from ES cells and qPCR 
was carried out using two primer/probe sets. Fold change was calculated using the 2-ΔΔCT method 
as compared to wild type DNA. In correctly targeted ES cells (6F9, 6H9, 10H10) the 
primer/probe set located on the NeoR insertion site (RQ) is expected to have a 50% fold 
reduction compared to wild type, while the exon 14 primer/probe set should have no fold change. 
8G8 shows ES cells with no integration. 
 
2.4 Confirmation of RASA1 R780Q protein expression    
  Rasa1fl/R780Q mice were intercrossed in order to generate homozygous RASA1 R780Q 
embryos.  At E9.5, embryos were harvested, and DNA was isolated from yolk sacs for 
genotyping. Genotyping was carried out using the same PCR primers used to determine NeoR 
cassette deletion, as the presence of the loxP site generates products of a longer length than that 
of the Rasa1 R780Q allele with the FRT site (685 vs 604) (Figure 8).  Embryos were minced and 
digested to isolate murine embryonic fibroblasts (MEF), which were grown in culture in 
fibroblast media until confluent. Protein was isolated from an equivalent number of cells and 
Western blotting was done to determine level of RASA1 protein present in embryos of all 
genotypes (Figure 8).  Blots were reprobed with an anti-glyceraldehyde-3-phosphate 
dehydrogenase antibody (GAPDH) as a loading control.  Homozygous RASA1 R780Q embryos 
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expressed the same levels of RASA1 protein as Rasa1fl/fl littermates, which would be consistent 
with the fact that the mutation does not affect the tertiary structure of RASA1 in a manner that 
that might lead to increased degradation. 
 
 
Figure 8. Genotyping Rasa1 R780Q embryos and expression of RASA1 R780Q protein in 
homozygous embryos. Left, DNA from embryos was isolated and PCR amplified using primers 
described above. Top band (685bp) is the floxed allele, bottom band (604bp) is the R780Q allele. 
Right, MEFs derived from E9.5 Rasa1 R780Q/R780Q (rq/rq) and Rasa1 fl/fl (fl/fl) embryos were 
analyzed for RASA1 protein levels using Western blot analysis. Blots were reprobed for 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) to show equivalent protein loading. 
Shown are RASA1 amounts in MEF derived from two different embryos of each genotype, 
representative of n=3. 
 
2.5 Materials and Methods 
 2.5.1 Generation of R780Q knock-in allele 
A Rasa1 R780Q targeting construct was assembled in p-loxP-2FRT-PGKneo. A 5’ arm that 
contained introns 13 through 17 of the Rasa1 gene was generated by PCR from a C57BL/6 
genomic Rasa1 BAC clone and inserted into the EcoRI/KpnI sites of the vector. The primers 
used were: 5’ arm forward, 5’-GCGCGAATTCGCGGCCGCTTAGTCTTTCAGGCATTT-
TATAGC-3’; and 5’ arm reverse, 5’-GCGCGGTACCGAATGCTTATTTACCAGGAGTGAC-
3’. A middle segment spanning intron 17 through 18 was generated by PCR from the same 
Rasa1 BAC clone that contained a CGA to CAA codon change resulting in a R780Q mutation in 
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exon 18 that was generated by homologous recombination in Escherichia coli. The middle 
fragment was inserted into the KpnI and 3’ BglII sites of the vector. The primers used were as 
follows: M forward, 5’-GCGCGGTACCAGATCTAAATATTTGAGCCTATGAGGACC- 
ATTC-3’; and M reverse, 5’-GCGCGGATCCCATATCCAACTTCACATGATGTGC-3’. A 3’ 
arm that spanned introns 18 through 20 was generated by PCR from the wild-type Rasa1 BAC 
clone and was inserted into the XhoI site of the vector. The primers used were as follows: 3’ arm 
forward, 5’-GCGCCTCGAGGAATTTCCCACATGGA-3’; and 3’ arm reverse, 5’-
GCGCCTCGAGATATGTTGTCATGTAA-3’.  The targeting construct was sequenced to verify 
the absence of any PCR-induced errors. The construct was electroporated into W4 embryonic 
stem (ES) cells that were subsequently cultured in neomycin. 
 Genomic DNA from neomycin-resistant ES cell clones was analyzed by qPCR using an 
integration primer/probe set in which the 5’ and 3’ primers flanked the FRT-NeoR-FRT insertion 
site and the probe was complimentary to regions both 5’ and 3’ to the point of insertion [87].  
Fold differences in the amount of exon 18 target relative to that in genomic DNA prepared from 
wild-type W4 ES cells were calculated as described [86]. Clones that demonstrated a twofold 
reduction in the intron 18 target were analyzed further by qPCR using a copy number 
primer/probe set based within exon 14 of the Rasa1 gene (Life Technologies). Of those clones 
that contained diploid amounts of the exon 14 target, a long-range PCR was performed using a 
Rasa1 forward primer based on the 5’ of the 5’ end of the Rasa1 targeting vector insert and a 
reverse primer based in intron 18. A similar long-range PCR was performed using a forward 
primer based in intron 18 and a reverse primer located 3’ of the 3’ end of the Rasa1 targeting 
vector insert. Both PCR products were sequenced to confirm the presence of the R780Q 
mutation within the endogenous Rasa1 locus. 
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Two of several correctly targeted Rasa1 R780Q clones were injected into C57BL/6J X 
(C57BL/6J X DBA/2) blastocysts to generate chimeric mice that were then bred with C57BL/6 
actin promoter-driven Flp transgenic mice to achieve germline transmission of the targeted 
Rasa1 R780Q allele and deletion of the NeoR cassette in intron 18 [88]. Germline transmission 
and NeoR deletion were determined by PCR of tail genomic DNA prepared from agouti coat-
colored progeny using a forward primer based in exon 18 and a reverse primer based 3’ to the 3’ 
FRT site in intron 18. Germline transmitted mice were then crossed with C57BL/6 mice and the 
same PCR was performed on tail DNA of progeny that had not inherited the actin-Flp transgene, 
also determined by PCR. This step was undertaken to obtain mice with confirmed germline 
deletion of the NeoR cassette within the Rasa1 R780Q locus. 
 
2.5.2 Western Blotting for RASA1 expression 
Individual E9.5 embryos were minced and digested in trypsin/EDTA (Life Technologies) 
at 37°C for 15 minutes. MEFs were generated by culture of released cells in fibroblast media 
(Dulbecco’s modified Eagle’s medium, 10% fetal bovine serum, 1% penicillin/streptomycin, and 
1% L-glutamine). At confluence, MEFs were harvested and 3 x 106 cells were lysed in 1% NP-
40 lysis buffer. RASA1 protein abundance was determined by using Western blot analysis of cell 
lysates using an anti-RASA1 antibody (B4F8; Santa Cruz, Dallas, Q6 TX). Blots were stripped 
and reprobed with an anti-GAPDH antibody (Santa Cruz) to ascertain equivalent protein loading. 
 
2.6 Discussion 
 We have successfully designed and implemented a targeting scheme which resulted in the 
generation of a mouse carrying a Rasa1 R780Q point mutation, which was confirmed by 
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sequencing.  R780Q RASA1 protein is expressed at normal levels, as there is no difference in 
protein level between homozygous R780Q MEF and wild type MEF.  The generation of the 
Rasa1 R780Q knock-in mouse will allow for further exploration of the function of RASA1 in the 
development of the mouse cardiovascular system and maintenance of the lymphatic vasculature.  
This work has translational implications as it will permit identification of which pathways 
disrupted as a consequence of loss of RASA1 are responsible for cardiovascular and lymphatic 
abnormalities in CM-AVM. In turn this could inform as to potential new therapies for CM-AVM 
patients. 
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Chapter 3 
The GAP domain of RASA1 is required for normal cardiovascular development and 
lymphatic vessel maintenance 
 
3.1 Abstract 
 p120 RasGAP (RASA1) is the prototypical Ras GTPase activating protein, identified as a 
regulator of Ras signaling.  It has since been shown to regulate distinct pathways in a Ras-
independent manner. These interactions are mediated by domains other than the GAP domain 
that is essential for stabilization of Ras and efficient GTP hydrolysis.  Previously reported non-
conditional and tissue specific Rasa1 gene disrupted mice completely lack RASA1 protein in all 
or targeted tissues, respectively.  Absence of Rasa1 in mice causes embryonic lethality due to 
failed cardiovascular development, while loss of Rasa1 in adult mice results in lymphatic 
hyperplasia and leakage.  In humans with the disorder capillary malformation-arteriovenous 
malformation (CM-AVM), mutations in RASA1 span the length of the gene, and along with 
second hit mutations of the wild type RASA1 allele are also believed to result in complete loss of 
protein. In all of these cases, the loss of RASA1 could result in the perturbation of multiple 
different pathways and cell processes.  In order to determine if phenotypes result from loss of an 
ability of RASA1 to regulate Ras or not, a knock-in mouse carrying a point mutation that ablates 
RASA1’s GAP activity while maintaining other potential functions of the protein was generated. 
In its homozygous form, the Rasa1 knock-in allele is embryonic lethal due to impaired 
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cardiovascular development. Embryonic lethality occurs at the same time as observed in RASA1 
null embryos and is associated with failed yolk sac vascularization and aberrant vascularization 
in the embryo proper.  Generation of mice that are heterozygous for a Rasa1 knock-in allele and 
a conditional floxed Rasa1 allele and which also carry an inducible ubiquitin promoter-driven 
ert2Cre transgene were generated. These mice allow for examination of the importance of loss of 
RASA1’s activity to regulate Ras to the development of the lymphatic disease that results upon 
loss of Rasa1 in adults.  Mice that were induced to express RASA1 R780Q alone develop 
striking lymphatic hyperplasia and leakage before succumbing to chylothorax.  The severity and 
time of onset of lymphatic disease was similar to that observed in the induced Rasa1 deficient 
mice. Induced loss of an ability of RASA1 to regulate Ras is responsible for the development of 
both the cardiovascular and lymphatic phenotypes in Rasa1 deficient mice.  This has important 
implications for the treatment of patients with CM-AVM, as it suggests that inhibitors of 
downstream effectors of Ras may be effective in the treatment of this disease. 
 
3.2 Introduction 
 Ras is a small membrane bound GTP-binding protein that is activated downstream of 
multiple different cell surface receptors [1].  Ras guanine nucleotide exchange factors (RasGEF) 
eject GDP from inactive Ras and allow Ras to bind GTP, resulting in activation of multiple 
different pathways, including the MAPK and PI3K/AKT pathways [3, 6, 7].  Activation of these 
pathways results in cell survival, proliferation, and differentiation. Cessation of this signaling is 
dependent on the hydrolysis of Ras-GTP to Ras-GDP.  While Ras has some innate GTPase 
activity, Ras GTPase activating proteins increase GTP hydrolysis by several orders of magnitude 
[2]. Originally identified as a RasGAP, p120 RasGAP (RASA1) interacts with Ras via its GAP 
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domain.  The GAP domain contains an arginine finger that is essential for stabilizing Ras in the 
correct confirmation for Ras to efficiently hydrolyze GTP.  
Along with Ras, RASA1 has been shown to interact with multiple other proteins through 
its modular binding domains.  One such protein is p190 RhoGAP, which interacts with RASA1’s 
N-terminal SH2 domain [56].  RASA1 interactions with p190 RhoGAP have been shown to be 
important in directed cell movement, as disruption of this complex impairs actin filament 
rearrangement and orientation [55].  RASA1 also interacts with DLC1, a RhoGAP, via its SH3 
domain [57].  RASA1 inhibits DLC1 activity, leading to the increase in RhoA activation which 
drives increased cell proliferation.   
By replacing the SH2 domain of RASA1 with a Neomycin resistance cassette, RASA1 
protein expression was ablated [37]. Heterozygous RASA1 deficient embryos develop normally 
and have no obvious phenotype, and can be intercrossed to generate homozygous RASA1 null 
embryos. Mice deficient of RASA1 are not viable, and die in utero around E10.5. The yolk sac 
of these embryos fail to develop vascular networks, with the endothelial cells failing to rearrange 
from a honeycomb pattern. Within the embryo proper, the dorsal aortas are thinner than either 
wild type or heterozygous RASA1 deficient littermates, and they have aberrant branching of 
intersegmental arteries.  
In order to bypass the embryonic lethality, mice with a conditional allele of RASA1 were 
generated [83].  These mice have loxP sites up- and downstream of exon 18, allowing for Cre 
recombination that results in nonsense mediated RNA decay and complete loss of protein.  
Ubiquitous deletion of RASA1 in adult mice by tamoxifen injection in Rasa1fl/fl ub-ert2cre mice 
results in a striking lymphatic hyperplasia [38]. The lymphatic vasculature is also extremely 
dilated and leaky, and mice develop chylous ascites and chylothorax, to which the mice 
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succumb. The lymphatic endothelial cells (LEC) are highly proliferative, with aberrant biphasic 
pERK and pAKT signaling through vascular endothelial growth factor receptor 3 (VEGFR3). 
Mice with loss of RASA1 specifically in LEC develop the same phenotype.  Interestingly, 
ubiquitous loss of RASA1 in adults does not result in any spontaneous cardiovascular phenotype, 
although there is some data that suggests RASA1 inhibits angiogenesis in tumors [39]. 
 Humans with mutations in RASA1 develop capillary malformation-arteriovenous 
malformation (CM-AVM) with high penetrance [51]. CM-AVM is characterized by small 
multifocal dermal CM, with at least one third of patients also presenting with fast flow lesions 
including AVM, arteriovenous fistula, as well as  Parkes Weber syndrome [50].  Recently it has 
been identified that patients with CM-AVM also have lymphatic malformations [53]. Mutations 
in CM-AVM patients occur throughout the gene, and are believed to result in complete loss of 
expression from the mutated allele. Due to the variable nature of the disease, it is believed that 
second hit mutations occur to completely delete RASA1 protein from certain subsets of cells 
during development [51]. However, due to the predicted loss of the entire RASA1 protein, it is 
unknown what particular signaling pathways are responsible for the development of CM-AVM. 
 RASA1 promotes Ras GTP hydrolysis via a conserved arginine finger.  Mutation of the 
arginine in the arginine finger to a glutamine abrogates GAP activity while retaining the tertiary 
structure of the protein and allowing it to carry out putative other functions [84].  We have 
generated a knock-in mouse carrying a RASA1 R780Q point mutation in order to specifically 
study the role of loss of RASA1’s Ras directed catalytic activity in both the development of 
embryonic cardiovascular abnormalities and adult lymphatic vascular abnormalities.  We show 
here that both phenotypes result from the loss of RASA1’s ability to regulate Ras, resulting in 
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aberrant Ras activation. This work will have important translational implications in identifying 
potential treatments for patients with CM-AVM. 
 
3.3 Embryonic Lethality of Homozygous RASA1 R780Q mice 
 Rasa1 fl/R780Q mice were generated and intercrossed to generate Rasa1R780Q/R780Q mice.  
Multiple litters were genotyped at 3 weeks and no homozygous RASA1 R780Q pups were 
identified, which suggested that Rasa1R780Q/R780Q mice die in utero (Figure 9). In order to 
determine the time of embryonic lethality, timed matings were carried out and embryos were 
harvested and genotyped at multiple time points. Rasa1R780Q/R780Q embryos were identified in 
expected Mendelian ratios at E9.5, but were present in a less than expected number at E11 and 
absent at E13.5.  This is consistent with embryonic lethality around E10.5, i.e. at the same time 
of embryonic lethality as in RASA1 null mice.  
 
 
Figure 9. Rasa1R780Q/R780Q embryos are embryonic lethal mid-gestation. Graphs show the 
total number of pups of the indicated genotypes derived from intercrosses of Rasa1 R780Q/fl 
mice determined at 3 weeks after birth and at E9.5, E11, and E13.5 of development. At E9.5, 
genotype frequencies are consistent with mendelian inheritance (c2 test). At E11, E13.5, and 3 
weeks of age, genotype frequencies are not consistent with mendelian inheritance (P < 0.025, P < 
0.05, and P < 0.005, respectively). 
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 At E9.5, homozygous RASA1 R780Q embryos are easily distinguishable from control 
littermates (Figure 10).  Rasa1R780Q/R780Q embryos are grossly smaller in size with a distended 
pericardial sac.  The yolk sac of these embryos when removed is wrinkled in appearance.  Of the 
few E11 Rasa1R780Q/R780Q embryos that were identified the same phenotype was noted.  All of 
these features were also present in the complete RASA1 knockout E9.5 embryos [37]. 
 
 
Figure 10. Rasa1R780Q/R780Q embryos are identifiably different from littermate controls. 
Light microscopic appearance of Rasa1 R780Q/R780Q and Rasa1 R780Q/fl embryos and yolk 
sacs at E9.5. Rasa1 R780Q/R780Q embryos are reduced in size, and have a distended pericardial 
sac (arrow) and wrinkled appearance of the yolk sac. 
 
 
 To more closely analyze the vascular abnormalities in the E9.5 embryos, whole mount 
immunofluorescence was carried out on the embryos and yolk sacs using an anti-CD31 antibody 
to detect blood endothelial cells (BEC).  Both Rasa1fl/fl and Rasa1fl/R780Q littermate controls show 
normal blood vasculature development both in the yolk sac and the embryo proper (Figure 11).  
Yolk sacs are correctly vascularized, with vessels connecting to the embryo.  The embryos have 
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dorsal aortas with intersegmental arteries branching dorsally between somites, and the dorsal 
aorta is continuous and extends from the heart to posterior of the embryo. Whole mount staining 
with the BEC-specific anti-CD31 antibody shows that in contrast to wild type littermates, 
Rasa1R780Q/R780Q yolk sacs fail to develop a blood vascular network, with the endothelial cells 
arresting in a honeycomb pattern of fused blood islands (Figure 11).  The embryo proper has a 
thin, malformed dorsal aorta with irregular intersegmental arteries. Further analysis by 
immunohistochemistry using anti-CD31 in sections shows that the dorsal aorta is discontinuous 
in these embryos compared to control littermates.  The yolk sac and dorsal aorta phenotypes are 
the same as those of Rasa1 null E9.5 embryos [37].  
 
 
Figure 11. The blood vascular system of Rasa1R780Q/R780Q embryos does not develop 
correctly.  Whole mount Rasa1 R780Q/R780Q and Rasa1 fl/fl embryos were stained with an anti-
CD31 antibody to label blood vasculature. Rasa1 fl/fl yolk sacs have organized blood vessel 
networks while Rasa1R780Q/R780Q yolk sac blood vasculature is honeycombed in appearance. The 
homozygous R780Q embryo proper also had irregular blood vasculature. E, embryo; YS, yolk 
sac; IS, intersegmental artery; DA, dorsal aorta. 
 
 Predictably the R780Q RASA1 protein would not be able to promote Ras hydrolysis of 
GTP, which suggests that the cardiovascular phenotypes develop as a result of loss of control of 
Ras signaling. In order to confirm that Ras was dysregulated in Rasa1R780Q/R780Q embryos, E9.5 
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embryos were sectioned and stained with antibodies against the phosphorylated activated form of 
ERK MAPK (pERK) along with anti-CD31 to identify BEC. In both Rasa1 fl/fl and Rasa1fl/R780Q 
littermate control, pERK positive BEC were infrequently identified (Figure 12). However in 
Rasa1R780Q/R780Q embryos most BEC expressed pERK.  Thus, as expected, the Ras MAPK is 
aberrantly activated in BEC of homozygous R780Q mice. 
 
Figure 12. Rasa1R780Q/R780Q E9.5 embryo blood endothelial cells have activated Ras MAPK 
signaling. E9.5 embryos were sectioned and stained with anti-CD31 (red) in conjunction with 
anti-pERK (green) antibodies.  In control embryos, the majority of BEC do not express pERK, 
while in most Rasa1 BEC pERK is present.  
 
 
3.4 Loss of RASA1 regulation of Ras in adult mice 
 In order to address whether the lymphatic disease in adults originated from loss of 
regulation of Ras or loss of a Ras-independent function, Rasa1R780Q/fl ub-ert2Cre mice were 
generated.  Injection of mice with tamoxifen induces expression of the Cre recombinase 
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ubiquitously throughout the mouse, resulting in the deletion of the floxed allele and expression 
of only the RASA1 R780Q protein.  Mice were injected at 3 weeks of age, along with littermate 
Rasa1fl/fl ub-ert2Cre, Rasa1R780Q/fl and Rasa1fl/fl mice as positive and negative controls. 
  Approximately 10 weeks after tamoxifen injections, Rasa1R780Q/fl ub-ert2Cre mice 
developed labored breathing and were euthanized. Analysis of the euthanized mice showed that 
the entire thoracic cavity was filled with a pleural effusion (Figure 13).  Flow cytometry was 
carried out on the thoracic fluid to identify the cellular constituents.  The majority of non-
erythroid cells in the effusion were T- and B-cells, confirming that the fluid is chyle. 
 
 
Figure 13. Rasa1R780Q/fl ub-ert2Cre develop chylothorax. The chest cavities of Rasa1R780Q/fl ub-
ert2Cre mice fill with a milky fluid (left). Right, flow cytometry of pleural effusion. The 
majority of non-erythroid cells (Ter119-) are lymphocytes.  
 
 Organs were harvested from euthanized Rasa1R780Q/fl ub-ert2Cre mice for whole mount 
staining with anti-LYVE1 antibodies to identify LEC.  Diaphragms, ears, and trachea showed an 
increased density of lymphatic vessels as compared to littermate controls, similarly to Rasa1fl/fl 
ub-ert2Cre mice. Ribcages were sectioned and stained with anti-LYVE1. Lymphatic vessels are 
rarely found lining the pleural cavity of wild type littermate controls.  In contrast, Rasa1R780Q/fl 
ub-ert2Cre mice, the entire pleural face of the ribcage is lined with lymphatic vessels, similar to 
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the Rasa1fl/fl ub-ert2Cre mouse (Figure 14). Rasa1R780Q/fl ub-ert2Cre mice do not show a 
spontaneous cardiovascular phenotype, again similar to the Rasa1fl/fl ub-ert2Cre mouse [38]. 
 
 
Figure 14. The pleural face of Rasa1R780Q/fl ub-ert2Cre ribcages are lined with lymphatic 
vessels. Sections of ribcages were stained with anti-LYVE1 to identify lymphatic vessels. 
Control ribcages rarely have lymphatic vessels on the pleural face, while Rasa1R780Q/fl ub-ert2Cre 
mice have multiple vessels lining the entire pleural cavity. 
 
 As loss of the RASA1’s GAP domain results in the same lymphatic hyperplasia and 
leakage as the complete conditional knockout, we hypothesized that there would be aberrant Ras 
signaling in LEC.  Serial sections of ribcage were stained with anti-LYVE1, anti-CD31, and anti-
pERK antibodies in order to identify LEC and BEC where active Ras signaling was present.  
Interestingly, the majority of lymphatic vessels do not express high levels pERK, while the 
majority of blood vessels have pERK present (Figure 15). Despite the active Ras MAPK 
signaling in BEC, these mice do not develop any spontaneous cardiovascular phenotypes.  
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  CD-31    LYVE-1   pERK 
 
Figure 15. Rasa1R780Q/fl ub-ert2Cre mice have active Ras MAPK signaling in BEC but not in 
LEC. Serial sections of Rasa1R780Q/fl ub-ert2Cre ribcages were stained to identify blood and 
lymphatic vessels along with pERK. Left, anti-CD31 staining, middle, anti-LYVE1 staining, and 
right, anti-pERK staining. Dotted lines identify specific vessels. 
 
3.5 Materials and Methods 
 3.5.1 Whole Mount Staining 
 E9.5 embryos were fixed in 1% paraformaldehyde in phosphate-buffered saline. Fixed 
embryos were stained with a rat anti-CD31 antibody (BD Biosciences), followed by a secondary 
goat anti-rat Ig Alexa Fluor 488 antibody (Invitrogen). Images of embryos were acquired on an 
Olympus BX60 upright fluorescence microscope equipped with a digital camera (Nikon).  
 
 3.5.2 Immunohistology 
E9.5 embryos were fixed in formalin and embedded in paraffin. Sections (5 mm thick) 
were stained with a rabbit anti-phospho-extracellular signal regulated kinase (ERK) antibody 
(D13.14.4E; Cell Signaling), followed by biotinylated anti-rabbit Ig (Jackson Immunoresearch) 
and streptavidin-horseradish peroxidase with tyramide signal amplification (Perkin Elmer, 
Waltham, MA). Sections were then stained with a rat anti-CD31 antibody (sz31; Dianova), 
followed by secondary goat anti-rat Alexa Fluor 594 (Invitrogen). Some sections were stained 
with CD31 and secondary antibody alone or with hematoxylin and eosin. Images of sections 
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were acquired as described in the Whole Mount Staining section. Rib cage sections were stained 
with rabbit anti-LYVE1 (AbCam) followed by goat anti-rabbit Alexa Fluor 488 (Invitrogen), as 
well as CD31 and pERK as described.  
 
3.5.3 Flow Cytometry 
Cells isolated from Rasa1R780Q/fl ert2Cre pleural effusion were stained with 
fluorochrome-coupled anti-CD4, anti-CD8, anti-TCR, anti-BB20, anti-GR1, and anti-CD11b.  
Cell staining was analyzed by use of a FACS Canto.  
 
3.6 Discussion 
 In its homozygous form, the Rasa1 R780Q allele results in embryonic lethality of 
embryos mid-gestation, the timing of which is similar to that of RASA1 null embryos.  Embryos 
have thin, discontinuous dorsal aortas with aberrant projects, and failed blood vessel 
reorganization in the yolk sac. BEC in these mice express increased levels of pERK as compared 
to wild type littermate controls. Thus, this blood vessel disorder is due to aberrant Ras activation 
through loss of RASA1’s ability to promote Ras GTP hydrolysis. This has important 
implications for treatment options for patients with CM-AVM. Inhibitors of Ras downstream 
effectors, including ERK1/2, are already in clinical use. It is possible that treatment of these 
patients with ERK inhibitors during development may alleviate the severity of disease. The 
efficacy of these inhibitors as treatments for these patients can be tested in Rasa1R780Q/R780Q 
embryonic development to see if they rescue blood vessel organization in these embryos. 
 Interestingly, overexpression of Ras in embryos results in lymphatic hyperplasia, with no 
impairment of cardiovascular development [89]. It is possible that this occurs because the 
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lymphatic system is more sensitive to aberrant Ras activation than the blood vascular system. As 
this model of Ras overexpression is not refractory to RasGAPs, it is possible that this level of 
Ras signaling can be controlled effectively enough by RASA1 in BEC to maintain normal 
development and function. However, in lymphatic vessels, it may be that this level of 
overexpressed Ras is not efficiently controlled enough, especially downstream of VEGFR3.  
Loss of the complete RASA1 protein in adult mice results in severe lymphatic 
hyperplasia and leakage, resulting in death by chylothorax. In order to investigate the role of 
RASA1’s promotion of Ras GTP hydrolysis in the development of the lymphatic phenotype, 
mice were generated that have an allele with a point mutation that abrogates RASA1’s GAP 
activity in conjunction with a floxed allele of RASA1 and a ubiquitously expressed Cre 
recombinase transgene. Induction of deletion of the conditional allele in adult mice 3 weeks of 
age results in death by chylothorax around 10 weeks post injection.  These mice have increased 
lymphatic vessel density in multiple organ systems, including diaphragm and ribcage.  However, 
no aberrant blood vascular phenotype was identified. This phenotype is consistent with mouse 
models of overexpression and knockouts of Ras, in which embryos develop lymphatic hyper- 
and hypoplasia, respectively [89].  
 Since the phenotype develops through loss of correct Ras regulation, lymphatic vessels 
were screened for aberrant activation of Ras downstream effectors.  Interestingly, high Ras 
MAPK activation levels were identified in BEC, but is comparatively rare in LEC composed 
vessels. This is consistent with the expression of active pERK in the BEC of the Rasa1R780Q/R780Q 
embryos. However, in the Ras overexpression lymphatic hyperplasia model and the conditional 
Rasa1 model, the LEC have aberrant Ras MAPK signaling through VEGFR3 [38, 89].  It is 
possible that detection of pERK in sections is not a sensitive enough form of readout for aberrant 
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Ras signaling in lymphatic vessels. Further work would include isolating LEC from Rasa1R780Q/fl 
ert2Cre mice and stimulating them with growth factors, then using Western blotting to follow 
activation of Ras downstream effectors.  
 As the lymphatic vessel hyperplasia and leakage develops specifically due to loss of 
RASA1’s ability to promote Ras GTP hydrolysis, this suggests that lymphatic malformations in 
CM-AVM patients are due to aberrant Ras activation.  Again, inhibitors of Ras downstream 
effectors may be a potential treatment for CM-AVM patients. However, recent attempts to use 
these inhibitors in Rasa1fl/fl ert2Cre mice had not been successful at delaying or preventing the 
lymphatic vessel hyperplasia. Further work in this area will be to use mice with mutations in 
genes in the Ras MAPK and PI3K pathways and cross them with Rasa1R780Q/fl ert2Cre or 
Rasa1fl/fl ert2Cre mice to see if impairment of downstream effector pathways can rescue the 
lymphatic phenotype. 
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Chapter 4 
RasGAPs p120 RasGAP and Neurofibromin1 act in concert as tumor suppressors during T 
cell development 
 
4.1 Abstract 
 Ras GTPase activating proteins (RasGAPs) are essential for regulation of Ras signaling 
downstream of multiple different receptors. Activation of Ras is dependent on the recruitment of 
Ras guanine nucleotide exchange proteins (RasGEFs). The RasGEFs essential for Ras activation 
downstream of the TCR are well characterized. However, the RasGAP that is essential for 
cessation of Ras signaling downstream of the TCR is unknown. Singular loss of the RasGAPs 
p120 RasGAP (RASA1) and Neurofibromin 1 (NF1) in the T cell compartment have failed to 
identify the required RasGAP, as these mice develop subtle T cell phenotypes.  Loss of both 
RASA1 and NF1 in embryos results in earlier embryonic lethality, suggesting they have 
overlapping function in the same pathway. To explore the possibility that these RasGAPs work 
in concert in T cells, RASA1 and NF1 were concurrently deleted in developing thymocytes.  
While no defects were found in number or percentages of thymocyte subpopulations, over half 
the double deficient mice develop lethal T cell acute lymphoblastic leukemia/lymphoma (T-
ALL).  The T-ALL develop early in T cell development and are dependent upon strongly 
activating mutations in Notch1. Analysis of freshly isolated T-ALL cells shows increased basal 
47 
 
Ras signaling through the MAPK and PI3K/AKT signaling pathways compared to wild type 
cells, suggesting that Ras signaling acts downstream of Notch1 mutations in tumor formation.    
 
4.2 Introduction 
 Ras signaling has a wide range of functions, from driving cell proliferation to 
differentiation and survival [1]. Ras acts as a molecular switch, as it is inactive when bound to 
GDP but becomes active upon binding to GTP.  Inactive Ras requires Ras guanine nucleotide 
exchange factors (RasGEFs) for ejecting the bound GDP and allowing binding of GTP, which is 
in higher concentration than GDP within the cell cytosol.  Ras signals through multiple 
downstream pathways including MAPK and PI3K [3, 6, 7].  This signaling requires careful 
regulation, as aberrant Ras signaling often results in the development of cancer [13]. Although 
Ras has some intrinsic GTPase activity, efficient cessation of signaling requires Ras interaction 
with Ras GTPase activating proteins (RasGAPs) which increase Ras GTPase activity by several 
orders of magnitude [2].  
 Ras signaling is essential for correct T cell development and activation. ERK1/2 
activation through MEK1 downstream of Ras are essential for positive selection, and ERK1 and 
2 have individual roles in DN stage progression [29-31]. Once past positive selection, DP 
thymocytes undergo negative selection to avoid the generation of autoreactive T cells. Ras 
signaling is also involved in TCR signaling, where it is well characterized that the RasGEFs 
RasGRP1 and Sos are recruited after TCR signaling to activate Ras [35, 36].  However, the 
negative regulation of Ras both in T cell development and downstream of the TCR is not 
understood. 
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 Failure to regulate Ras can result in the development of multiple different cancers.  
Mutations of Ras that make them refractory to RasGAP activation or otherwise constitutively 
active are found in 30% of all cancers [11]. Murine models of Ras overexpression have been 
generated utilizing a K-rasG12D allele, and these mice develop various cancers dependent on the 
tissue of expression [14, 15].  Transfer of K-rasG12D bone marrow into lethally irradiated wild 
type recipients results in the mice developing an aggressive T cell acute lymphoblastic leukemia 
[16]. 
 Along with activating Ras mutations, murine models of T-ALL often carry secondary 
mutations that are required for the genesis of the cancer [16, 78]. The Notch1 protein undergoes 
gain of function mutations in over 50% of human T-ALL cases [69].  In murine models of T-
ALL HD mutations are rare, but PEST domain mutations are still common [78].  More recently 
two new types of murine Notch1 mutations were described [79, 80]. Type 1 mutations (NT1) are 
recombination activating gene (RAG)-mediated recombinations that splice out exons 1 and 2, 
while Type 2 mutations (NT2) are RAG-independent recombinations that result in loss of exons 
2 through 25 or 26.  In both cases, this results in translation from an internal methionine and 
generation of a transmembrane protein that undergoes ligand-independent cleavage. 
 While correct regulation of Ras signaling in T cells is clearly essential, how Ras is 
regulated either in developing cells or downstream of TCR activation is yet unknown.  Single 
loss of the RasGAP p120 RasGAP (RASA1) specifically in developing thymocytes results in a 
slight increase in positive selection in the thymus along with reduced numbers of naïve cells in 
the periphery only when on a transgenic TCR background [40].  Similarly, thymocyte specific 
deletion of the RasGAP Neurofibromin 1 (NF1) on a TCR transgenic background results in 
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impaired positive selection in the thymus and a decrease in naïve peripheral T cells [63]. Thus, 
the RasGAP or GAPs essential for efficient Ras GTP hydrolysis in T cells are still unknown. 
  It has been previously shown that RASA1 and NF1 have overlapping functions in the 
same pathway during embryonic development, as embryos deficient for both RasGAPs have 
earlier timing of embryonic lethality than the lethality due to loss of either RasGAP alone [37]. 
We hypothesized that these RasGAPs may play a cooperative role in regulating Ras in T cells. 
To address this, mice with conditional alleles of both RASA1 and NF1 with and without a 
thymocyte specific Cre transgene were generated. We show that while T cell development and 
function in these mice are unaffected, mice with concurrent deletion of RASA1 and NF1 in the T 
cell compartment undergo early lethality due to the development of T-ALL.  We further show 
that the T-ALLs carry activating Notch1 mutations, and that aberrant Ras signaling is most likely 
important downstream of these mutations for the generation of T-ALL. 
 
4.3 Generation of Double Knockout Mice and Analysis of T cell development 
 In order to address the possibility of overlapping Ras regulation by RASA1 and NF1 in T 
cells, Rasa1fl/fl and Nf1fl/fl mice were crossed to generate Rasa1fl/flNf1fl/fl mice with and without 
pLck-Cre. These mice develop normally into adulthood.  At 5 weeks of age, thymi were isolated 
from Rasa1fl/flNf1fl/fl pLck-Cre (pLCK-DKO) mice and Rasa1fl/flNf1fl/fl littermate controls.  Flow 
cytometry was carried out to identity developmental populations of thymocytes and determine if 
there were any aberrations in T cell development in the double deficient mice.  There were no 
significant differences in either the number or percentages of DN subsets in pLCK-DKO mice 
compare to control mice.  A small decrease in the numbers of some DP subpopulations were 
observed, however these decreases were similar to those found in Nf1fl/fl pLck-Cre mice and did 
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not result from compound loss of NF1 and RASA1 [63]. Small decreases in single positive 
thymocytes were also noted but were similar to the reduction found in both Nf1fl/fl pLck-Cre and 
Rasa1fl/fl pLck-Cre mice [40, 63].  Mature T cells were isolated from 5 week old mice and were 
stimulated through the TCR and CD28 costimulation receptor. There was no apparent defect in 
cytokine production from pLCK-DKO T cells (unpublished data, Philip Lapinski). 
 
4.4 Development of T cell Acute Lymphoblastic Leukemia/Lymphoma 
While the thymocytes and T cells of pLCK-DKO mice appear to develop and function 
normally, these mice succumb early, starting at around 3 months of age and affecting 60% of 
mice by 20 months of age (Figure 16).  Gross analysis of these mice shows a greatly enlarged 
thymus that fills the entire thoracic cavity, resulting in labored breathing and eventual 
suffocation due to impaired lung function.  Other lymphoid organs and liver are also grossly 
enlarged.  
 
 
Figure 16. Lymphoid organs from euthanized pLCK-DKO mice are grossly enlarged. Left, 
survival curve of pLCK-DKO mice compared to littermates. Right, Lymphoid organs isolated 
from an 8 month old moribund pLCK-DKO mouse are much larger than the same organs from a 
littermate control. MLN, mesenteric lymph node; LN, lymph nodes. 
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 Histological analysis was carried out on the hematopoietic organs and shows a loss of 
normal organ structure (Figure 17).  Within the thymus, there is a loss of differentiation between 
the cortex and the medulla.  This breakdown in structure is also found in the spleen, which is 
comprised entirely of lymphocytes with loss of red and white pulp.  The liver also shows signs of 
infiltration with large numbers of perivascular lymphocytes. Higher power analysis shows a 
starry sky appearance in spleen and lymph nodes, which is due to the presence of macrophages 
engulfing cellular debris. This is a classic feature of lymphomas. 
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Figure 17. Lymphoid organs and liver from moribund pLCK-DKO mice. Top, 8 month old 
moribund pLCK-DKO and litter mate control thymus and spleen. C, cortex; M, medulla; W, 
white pulp; R, red pulp. Bar represents 400µm. Bottom left, liver of moribund pLCK-DKO and 
control. Arrowhead points to perivascular infiltration of lymphocytes. Bar represents 400µm. 
Bottom right, higher magnification of moribund pLCK-DKO spleen and mesenteric lymph node 
(MLN) to highlight starry sky appearance. Bar represents 100µm.  
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 Flow cytometric analysis was carried out on the thymocytes of moribund pLCK-DKO 
mice.  Thymocytes from sick mice were consistently CD8+ with variable CD4 expression, and 
these cells were the majority of cells identified in spleen, lymph node, and blood (Figure 18).  
Further analysis of the cells showed that they expressed lower levels of TCRβ and had increased 
expression of CD25. DNA was isolated from these cells and copy number quantitative PCR 
(qPCR) was carried out to confirm deletion of Rasa1 and Nf1 using primer/probe sets located in 
regions deleted by Cre recombination (Figure 19).  All mice showed near complete deletion of 
both genes, confirming that this phenotype is due to combined loss of both RasGAPs.  
 
  
Figure 18. Cell surface phenotype of pLCK-DKO T-ALL cells. Left, cells isolated from 
thymus, spleen, and peripheral blood (P. Blood) of moribund 6 month old pLCK-DKO mouse 
and littermate control and stained with anti-CD8 and CD4 antibodies. Right, splenocytes from 
moribund 6 month old pLCK-DKO mouse and littermate control were gated on CD8+ cells. 
CD25 vs CD44 plots show pLCK-DKO CD8+ cells express CD25. Histograms of TCRβ 
expression show pLCK-DKO CD8+ cells have lower TCRβ expression than littermate control 
CD8+ cells. 
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Figure 19. RASA1 and NF1 gene disruption in T-ALL. Genomic DNA was prepared from 
thymocytes from wild type (WT) mice and seven different moribund pLCK-DKO mice. Relative 
amounts of intact Nf1 and Rasa1 genes were determined by qPCR. Values are expressed as a 
percent of gene abundance in WT mice. 
 
 The T cell phenotype developed by pLCK-DKO mice is very similar to other reported 
mouse models of T-ALL. In order to confirm T-ALL, thymocytes were taken from a moribund 
mouse and injected into sublethally irradiated wild type recipients. Within two months, recipients 
became moribund.  Isolation of spleens and lymph nodes showed the same large population of 
CD8+CD4variable cells found in the donor mouse (Figure 20). All these data taken together 
suggested that these mice develop a spontaneously occurring T-ALL dependent on combined 
loss of both Rasa1 and Nf1 in the T cell compartment. 
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Figure 20. pLCK-DKO T-ALL is transferrable to sublethally irradiated recipient mice. 
Left, CD8+CD4variable cells infiltrate peripheral lymphoid organs such as spleen and lymph 
nodes in sublethally irradiated mice (LN). Right, the T-ALL cells retain their TCRβ low 
phenotype. 
 
4.5 T-ALL cells carry strongly activating Notch1 mutations 
 Notch1 mutations are common in the majority of both human and murine T-ALL, 
although the types of mutations vary.  Common mutations in murine T-ALL models include 
PEST domain mutations, which are not sufficient to drive T-ALL, along with Type 1 (NT1) and 
Type 2 mutations (NT2), which are strongly activating mutations. Human patients often have 
mutations in Notch1’s HD domain, but this is uncommon in mouse models.  DNA was isolated 
from pLCK-DKO T-ALL cells. HD and PEST domain mutations were screened for by 
amplifying and sequencing exons 26 and 27, and exon 34, respectively (Figure 21).  NT1 
mutations were identified by utilizing a PCR primer set that only results in a product when 
rearrangement has occurred.  NT2 mutations were detected by qPCR by determining the ratio 
between spliced out and unaffected exons.   
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Figure 21. Notch1 protein domains and associated mutations and screening protocols. Top, 
schematic of Notch 1 protein. EGF, epidermal growth factor; NLR, Notch Lin repeat; HD, 
heterodimerization domain; RAM, RBJ kappa-associated module; A, Ankyrin repeat; TAD, 
transcriptional activation domain; PEST, proline/glutamic acid/serine/threonine rich domain; 
NEC, Notch extracellular domain; ICN, intracellular Notch. Below, schematic depicting different 
types of possible Notch1 gene mutations. The wild type Notch1 gene is shown at center. 
Numbered boxes indicate exons and are aligned approximately with the protein domains that 
they encode. Primers used to detect PEST domain mutations in genomic DNA are shown as 
yellow arrowheads. In Notch1 type 1 (NT1) mutations (top), the region between the vertical blue 
bars that includes the 5’ promoter and exons 1 and 2 of Notch1 is deleted and transcription is 
initiated from a cryptic promoter upstream of exon 26. Translation is initiated from within exon 
27 (green arrow) to yield a form of Notch1 from which ICN is generated independently of Notch 
ligand. Red arrowheads indicate positions of PCR primers used to detect a 500 bp product from 
genomic DNA upon NT1 mutation. In Notch1 type 2 (NT2) mutations (bottom), DNA 
downstream of exon 1 is cut and spliced to DNA upstream of exon 26 or exon 27 (vertical 
orange bars) to yield transcripts from which translation is also initiated from within exon 27 
(green arrows), thereby resulting in a constitutively active form of Notch1. The presence of NT2 
mutations in samples was determined by qPCR using a primer/probe set (turquoise) to detect loss 
of exon 23 relative to WT thymocytes. Similar qPCRs were performed using a primer/probe set 
based in exon 31 (purple) as an additional control. 
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No pLCK-DKO mice had mutations in their HD domain, but 10 out of 11 T-ALLs had 
mutations in their PEST domain that resulted in truncated forms of the protein (Figure 22, Table 
2). Mutations were short insertion, deletion, or a combination of the two, leading to a frame shift 
and a premature stop codon.  These mutations occurred on one chromosome and were present in 
all the cells, suggesting that the T-ALLs arise from one precursor cell and are thus monoclonal. 
All T-ALLs also had Type 1 mutations, although it is unknown if Type 1 and PEST mutations 
occurred on the same chromosome (Figure 22, Table 2).  Three T-ALLs carried Type 2 
mutations. The T-ALLs with Type 2 mutations also had both Type 1 and PEST domain 
mutations (Table 2). Because of the recombinations involved in both Type 1 and Type 2, these 
rearrangements are mutually exclusive and must be on homologous chromosomes. 
 
 
Figure 22. All T-ALL carry activating Notch1 mutations. Shown are examples of NT1, PEST 
and NT2 Notch1 mutations in freshly isolated thymocytes from numbered pLCK-DKO mice with 
T-ALL, analyzed as described in Figure 21. The arrow on the PEST DNA sequence trace 
indicates the point of insertion of an AGGG sequence with resulting frameshift. Note equivalent 
height of base peaks at “N” positions on DNA sequence trace. Note also the 50% reduction in 
exon 23 abundance for T-ALL samples #5 and #12 compared to WT. 
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Table 2. List of pLCK-DKO T-ALLs and their associated Notch1 mutations. 
 
4.6 Ras signaling in pLCK-DKO thymocytes and T-ALL cells 
 As all the pLCK-DKO T-ALLs have NT1 mutations, these mutations must be an 
initiating event. Since NT1 mutations are RAG mediated, they must occur during stages of T cell 
development while RAG is active. This limits the possible precursor populations to late 
DN2/early DN3 to pre-positive selection DP stages [90].  Also limiting the populations is the 
expression of the pLck-Cre transgene, which does not induce deletion of Rasa1 and Nf1 until late 
DN2/early DN3 [91].  Since concurrent deletion of both RasGAPs is necessary for T-ALL 
development, it is possible that the loss of both RasGAPs results in aberrant Ras signaling that 
renders cells more permissive to Notch1 mutations. In order to address this theory, thymocytes 
were isolated from 5 week old pLCK-DKO mice and littermate controls, since pLCK-DKO mice 
do not develop T-ALL prior to approximately 12 weeks. Basal and stimulated levels of MAPK 
signaling were analyzed in pre-leukemic pLCK-DKO mice and littermate controls by phosphor-
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flow cytomtery. No significant changes in strength or duration of MAPK signaling were 
identified in pLCK-DKO DN3, DN4, DP, CD4+ or CD8+ populations (Figure 23). As Ras 
signaling can result in increased survival, it is also possible that pLCK-DKO cells that develop a 
mutation are more likely to escape apoptosis. However, pre-leukemic pLCK-DKO thymocyte 
survival was normal compared to littermate controls after undergoing multiple forms of apoptotic 
stimuli, and no increase in survival was identified in any of the developmental subpopulations 
(Figure 23). 
 
 
Figure 23. Pre-leukemic thymocyte populations have no change in MAPK signaling kinetics 
or survival after apoptotic stimuli. Left, representative plots from subpopulation analysis show 
neither increased strength nor duration of pERK signaling. DN3 cells from 5 week old pLCK-
DKO mice and littermate controls were either unstimulated (0) or stimulated with 50 ng/ml of 
PMA for 3, 10, or 30 minutes. Activation of Ras signaling was determined by flow cytometry 
using a phospho-specific ERK antibody. Right, pre-leukemic pLCK-DKO DN3 cells were 
treated with UV and gamma irradiation (.5 and 1.0 Gy), then cultured for 12 hours. Survival was 
determined by flow cytometry, with viable cells defined as Annexin V and 7AAD negative. 
Percent viability was calculated by taking the percent viable cells and normalizing it to the 
percentage of viable untreated thymocytes assigned a value of 100. Shown are the mean 
percentage + 1 SE (n= 3 mice of each genotype).  
 
  These data suggest that loss of RasGAP regulation of Ras may be more important 
downstream of Notch1 mutations. To test this, freshly isolated pLCK-DKO T-ALL cells were 
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analyzed using phospho-flow cytometry to analyze basal levels of MAPK and PI3K activity. 
Interestingly, both pathways showed slight but consistent increases in basal levels of activation 
compared to levels in littermate controls (Figure 24). This supports the hypothesis that Ras 
signaling acts downstream of Notch1 mutations for genesis of T-ALL. 
 
 
Figure 24. Freshly isolated T-ALL cells have increased basal levels of Ras downstream 
effector activation. Flow cytometry plots showing phospho-ERK (pERK) and phospho-AKT 
(pAKT) staining in freshly isolated DP thymocytes from two independent sick pLCK-DKO mice 
compared to DP thymocytes from age-matched littermate controls. 
 
 4.7 Materials and Methods 
 4.7.1 Mice 
 Rasa1fl/fl and Nf1fl/flpLck-Cre mice have been described previously [40, 63]. These mice 
were crossed to generate Rasa1fl/flNf1fl/fl mice with and without pLck-Cre. Genotypes were 
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determined by PCR of tail genomic DNA using the same PCR primers as described [40, 63].  
Mice were on a mixed129S6/Sv X C57BL/6 background. Moribund mice were euthanized and 
were recorded as end points in survival studies. All experiments were performed in compliance 
with University of Michigan guidelines and were approved by the University Committee on the 
Use and Care of Animals. 
 
 4.7.2 Flow Cytometry 
 Single cell suspensions were prepared from thymus, spleen and lymph nodes.  
Suspensions were stained with fluorochrome-labeled CD4 (GK1.5), CD8 (53-6.7), CD44 (IM7), 
CD25 (PC61), TCRβ (H57-597) (all BD Biosciences) and phospho-ERK1/2 (D13.14.4E) and 
phospho-AKT S473 (D9E) (both Cell Signaling) mAb as described previously [40, 63]. 
Apoptosis staining was done using Annexin V and 7AAD. Cell staining was analyzed by flow 
cytometry on a FACSCanto (BD Biosciences). 
  
 4.7.3 Tissue staining 
 Thymus, spleen, lymph nodes, and liver were fixed in 10% buffered formalin and then 
embedded in paraffin. Five micrometer sections of tissues were stained with H&E. Sections were 
imaged with an Olympus IX70 fluorescence microscope.  
 
 4.7.4 Quantitative PCR 
Genomic DNA was isolated from thymus tissue of mice with T-ALL (Qiagen). 
Efficiency of Rasa1 and Nf1 gene disruption was determined by qPCR using Taqman 
primer/probe sets based in deleted exons (Mm00404879_cn and Mm00351296_cn; Life 
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Technologies) and a 7500 Fast PCR machine (Applied Biosystems). A transferrin receptor 
primer/probe set was used as an internal control for all samples. The amount of intact wild type 
Rasa1 and Nf1 in T-ALL samples relative to thymi from Rasa1fl/flNf1fl/fl littermates was 
calculated as described [86]. 
 
4.7.5 Notch mutation analysis 
To identify Notch1 PEST domain mutations, genomic DNA from thymus was used as a 
template for PCR amplification of the entire exon of the Notch1 gene. PCR products were then 
analyzed by Sanger sequencing. To identify Notch1 Type 1 mutations, thymus genomic DNA 
was PCR-amplified using forward and reverse primers that flank exon 1 and 2 of the Notch1 
gene [79]. A 500bp product is only generated from a recombined Notch1 allele (Figure 21). To 
identify Notch1 Type 2 mutations, thymus genomic DNA was screened by qPCR using 
primer/probe sets located in exons 23 and 31 (Mm00539165_cn, Mm00539178_cn, Life 
Technologies) (Figure 21). A transferrin receptor primer/probe set was used as an internal 
control.  
 
4.8 Discussion 
 Ras activation in T cell development has been well characterized, from its activation to 
the role of specific downstream effectors [29-31, 34].  However, the negative regulation of Ras 
signaling during T cell development is not well understood.  Attempts to identify the RasGAP 
responsible for cessation of Ras signaling either downstream of the TCR or during thymocyte 
development have been unsuccessful, as loss of single RasGAPs results only in subtle thymocyte 
and T cell phenotypes [40, 63].  This suggests that either other RasGAPs are required for these 
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processes, or that multiple RasGAPs may have overlapping functions, resulting in normal T cell 
development and activation when only one RasGAP is lost. 
 Concurrent deletion of Rasa1 and Nf1 in the T cell compartment of mice resulted 
spontaneous lethal T-ALL.  Careful examination of the pre-leukemic thymocyte populations 
shows no gross changes in number or percentages between wild type and pLCK-DKO 
populations, other than those that were previously shown in the single T cell specific Rasa1 or 
Nf1 deleted mice. This suggests that concurrent loss of both RasGAPs does not impair normal T 
cell development for the majority of cells. Thus, the RasGAP – or RasGAPs – essential for 
thymocyte development, as well as those required for regulation of signaling downstream of 
MHC-TCR interactions, are still unknown. 
 However, over half of the pLCK-DKO mice develop T-ALL, indicating that RASA1 and 
NF1 act as co-regulators of Ras in tumor suppression in the T cell compartment. Deletion of 
either Rasa1 or Nf1 specifically in T cells never resulted in T-ALL in those mice. Loss of NF1 in 
the hematopoetic compartment in mice results in a myeloid proliferative disorder, while deletion 
of Nf1 in the Schwann cell linage along with Nf1 heterozygosity in the bone marrow results in 
plexiform neurofibromas, which are benign tumors [61, 62]. Germline mutations in NF1 in 
human patients lead to the disease Neurofibromatosis, which is characterized by multiple 
plexiform neurofibromas, and result in a high susceptibility for other neoplasms such as juvenile 
myelomonocitic leukemia (JMML) [64]. Thus, while there is precedent for NF1 as a tumor 
suppressor, loss of RASA1 has not been shown to result in any form of cancer in either mice or 
humans.  Thus, the development of T-ALL after loss of RASA1 and NF1 is the first known role 
of RASA1 as a tumor suppressor. 
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 Along with deletions of Rasa1 and Nf1, the T-ALL in pLCK-DKO mice harbor activating 
mutations in Notch1. Notch1 mutations are extremely common in both human T-ALL and mouse 
models, although the types of mutations may vary [16, 78, 92, 93]. Gain of function Notch1 
mutations arise in mice that already have other genetic alterations.  While Notch1 mutations in 
mice are well characterized, the interplay between the mutations in not fully understood.  Clearly 
in the RasG12D bone marrow transfer models of T-ALL, Notch1 mutations must occur after the 
activating Ras mutation. But just how this occurs is unknown. 
 In the pLCK-DKO mice, the potential population of origin is narrowed down to 
DN2/DN3 to DP based on the RAG-mediated recombination required for the NT1 mutation [79] 
and the activity of pLCK-Cre [91]. Our attempts to identify aberrant Ras signaling or increased 
survival after apoptotic stimuli failed to identify a particular population where these mutations 
may be arising, suggesting that the mechanism may not be due to aberrant Ras activation 
permitting Notch1 mutated cells to survive and/or expand.  Downstream of the Notch1 
mutations, freshly isolated T-ALL cells shows consistent, slight increases in Ras signaling, 
which suggests that Notch1 mutations occur randomly and loss of Ras regulation in these cells 
promotes tumor formation. This hypothesis has also been put forth to explain the T-ALL 
developed in mice that overexpress the RasGEF RasGRP1 [94]. We conclude that loss of both 
RasGAPs are essential for the development of T-ALL, while single loss of either RasGAP either 
results in the other RasGAP working in a compensatory manner, or the dysregulation of Ras fails 
to reach a threshold required for T-ALL to arise. Further work is required to fully understand 
how Ras signaling works downstream of NT1 mutations to drive T-ALL development.  
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Chapter 5 
Discussion and Future Directions 
 
 Ras signaling is involved in multiple cellular processes, and negative regulation of that 
signaling requires the activity of different RasGAPs. The RasGAP RASA1 has been shown to 
play an essential role in mouse cardiovascular development and lymphatic vessel maintenance 
[37, 38].  Humans with germline mutations of RASA1 are believed to gain second hit mutations 
of the wild type allele and develop CM-AVM due to complete loss of protein. This disease is 
characterized by cardiovascular abnormalities, with some patients presenting with lymphatic 
abnormalities [50, 53]. As both of these disorders are believed to be due to the complete loss of 
RASA1 protein, it is unknown whether the resulting cardiovascular and lymphatic phenotypes 
are due to loss of RASA1’s ability to promote Ras hydrolysis of GTP or loss of a Ras-
independent function. In order to address this question, we generated a knock-in mouse with a 
GAP-deficient RASA1 protein.  
 In Chapter 2 the construction of the knock-in mouse is described.  The arginine finger 
that is required to promote Ras GTP hydrolysis is mutated to a glutamine by changing a base pair 
in the codon (R780Q).  This point mutation does not disrupt the overall tertiary structure of the 
protein, allowing RASA1 to carry out putative other functions. We confirm that Rasa1R780Q/R780Q 
embryos express the same level of RASA1 protein as both heterozygote R780Q and floxed 
littermate controls. This knock-in mouse allows us to investigate the influence of RASA1’s GAP 
function on the development of cardiovascular and lymphatic phenotypes.  
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 In Chapter 3, we show that the homozygous Rasa1 R780Q embryos die in utero mid-
gestation due to failed cardiovascular development similar to that of the RASA1 null mice [37]. 
The Rasa1R780Q/R780Q embryos have thin, disrupted dorsal aortas with aberrant branching and 
failed blood vessel organization in yolk sacs as compared to littermate controls. Blood vessels in 
homozygous R780Q embryos all have increased Ras MAPK signaling compared to littermate 
controls, which confirms that it is aberrant Ras activation that is essential for the cardiovascular 
abnormalities. This has important implications for patients with CM-AVM, as it suggests that 
this disorder may be treatable with Ras MAPK pathway inhibitors that are already clinically 
available. It is possible that treatment with these inhibitors during development may ameliorate 
cardiovascular defects in patients. To test this, different approaches can be used. The inhibitors 
could be used on Rasa1R780Q/R780Q embryos to see if they rescue or at least improve the 
cardiovascular formation defects in these embryos. This could also be accomplished by 
intercrossing heterozygous RASA1 R780Q mice with mice with mutations in the MAPK 
pathway, to generate Rasa1R780Q/R780Q embryos with heterozygous loss of MAPK signaling. The 
embryos could then be analyzed to determine if a reduction in MAPK signaling allows for 
correct generation of the cardiovascular system. 
 Overexpression and knockouts of Ras result in lymphatic hyper- and hypoplasia, 
respectively, with no apparent cardiovascular defects [89]. This could possibly be explained by 
recent work showing that RASA1’s regulation of VEGFR3 signaling is dependent on 
localization through interactions with Ephrin receptors [95, 96]. Ephrin signaling is known to 
regulate both angiogenesis and lymphangiogenesis via VEGF signaling. One hypothesis could be 
that the lymphatic system is more sensitive to aberrant Ras signaling than the blood vascular 
system. In the overexpressed Ras model, the Ras is not refractory to RasGAP promoted GTP 
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hydrolysis, so it is possible that cardiovascular system development is correctly regulated by 
Ephrin receptor recruitment of RASA1, while the lymphatic system is not. This would fit with 
the fact that in RASA1 null or homozygous R780Q mice, the lack of RASA1 to promote Ras 
GTP hydrolysis results in uncontrolled Ras signaling in BEC leading to cardiovascular 
phenotype. This could be tested by impairing RASA1 recruitment by Ephrin receptors in mice 
overexpressing Ras, in an attempt to induce impaired cardiovascular development. 
Expression of only Rasa1 R780Q in adult mice results in lymphatic hyperplasia and 
leakage, similar to that of the Rasa1fl/fl ert2Cre mice [38]. Interestingly, while some lymphatic 
vessels expressed elevated pERK, the majority of blood vessels in these mice expressed pERK, 
despite the fact that there was no spontaneous cardiovascular phenotype noted. This is consistent 
with the activated MAPK seen in both RASA1 null and homozygous R780Q embryos. It is 
possible that in adult mice, the blood vessels are stable and the increased Ras signaling is not 
detrimental to vessel structure and function. However, in Rasa1fl/fl ert2Cre mice, isolated LEC 
have aberrant Ras signaling responses downstream of VEGFR3, including a second wave of 
activation that is not seen in LEC isolated from littermate controls. This suggests that the 
lymphatic vessels are experiencing dysregulated Ras signaling through the MAPK pathway. 
While it is difficult to find LEC in Rasa1R780Q/fl ert2Cre mice expressing pERK, Ras signaling 
could be analyzed by Western blot. Isolation of Rasa1R780Q/fl ert2Cre LEC, stimulation with 
VEGF-C, and probing for pERK, such as was done with the Rasa1fl/fl ert2Cre mice, would show 
if the loss of RASA1’s ability to promote Ras GTP hydrolysis results in the same aberrant 
pattern of activation. 
 Recent work in the laboratory has resulted in a hypothesis for the lack of obvious pERK 
signaling in the entirety of lymphatic vessels. Close inspection of the structure of the lymphatic 
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vessels in both Rasa1fl/fl ert2Cre and Rasa1R780Q/fl ert2Cre mice shows that the lymphatic vessel 
valves in these mice are disorganized.  Thus, we hypothesize that loss of RASA1 in these valve 
cells results in aberrant Ras signaling that results in loss of valve function and development. 
Valve cells express high levels of VEGFR3, and we have shown that mice without RASA1 have 
aberrant Ras activation downstream of VEGFR3. Overexpression of the VEGFR3 ligand VEGF-
C in mice results in chylothorax, suggesting these mice have impaired valve function [48]. We 
predict that RASA1 regulation of Ras signaling through VEGFR3 is essential for valve 
maintenance. In order to elucidate the function of RASA1 in valve cell maintenance, inhibitors 
of Ras effector molecules can be utilized to rescue the valve disruption phenotype in either 
Rasa1fl/fl ert2Cre of Rasa1R780Q/fl ert2Cre mice. These mice could also be intercrossed with mice 
with impairments in MAPK and PI3K pathways, to limit Ras signaling in an attempt to rescue 
valve maintenance. The importance of regulation of Ras signaling specifically in valve cells 
could explain why lymphatic vessels in adult mice are seemingly more sensitive to aberrant Ras 
signaling than blood vessels in RASA1 and RASA1 GAP deficient mice. 
 Recent attempts in the laboratory to inhibit the lymphatic phenotype in induced Rasa1fl/fl 
ert2Cre mice with inhibitors of AKT and Erk have been unsuccessful (PEL, personal 
communication). This is possibly due to the dosage used in the experiment, which can be 
avoided by use of mice with loss of these Ras effectors. Another possibility is that there is a 
different Ras effector that is essential for the development of the lymphatic hyperplasia and 
leakage. Other potential Ras downstream effectors include the Ras-like (Ral)  GTPase proteins 
RalA and RalB [97]. RalA and RalB are activated by RalGEFs, which contain Ras-association 
domains by which Ras and other Ras-family members can bind and activate them. Ral activation 
is involved in cell proliferation, including anchorage-independent proliferation in cancers, along 
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with vesicle transport and cytoskeletal organization [98]. In order to investigate the role of Ral 
activation in the Rasa1fl/fl ert2Cre lymphatic vasculature, lymphatic endothelial cells can be 
isolated and stimulated with VEGF-C, and GTP-bound Ral can be detected by pull-down and 
Western blot [99]. Further work could then include inhibition of Ral or Ral downstream effectors 
to determine effect on the lymphatic phenotype, or generation of RalA and RalB conditional 
mice could be used to remove Ral signaling in the lymphatic system. 
 In Chapter 4, we show that while single loss of the RasGAPs RASA1 and NF1 in mice 
result in subtle T cell phenotypes, concurrent loss of both RasGAPs specifically in the T cell 
compartment results in T cell acute lymphoblastic leukemia/lymphoma (T-ALL). Any 
perturbations in thymocyte subpopulation cell number or percentages is the same as the single 
knockout of one RasGAP, so any changes are not due to the additional loss of another RasGAP. 
Instead, over half the mice spontaneously develop T-ALL, which is not seen in either single 
knockout mouse. 
 The T-ALL that occur in these mice all have mutations in Notch1. These mutations vary, 
but all the T-ALL have at least one strongly activating mutation that would be sufficient to drive 
T-ALL. Due to the nature of the PEST domain mutations, we can conclude that these T-ALL are 
clonal, as the short insertions and/or deletions occur within all cells isolated. This suggests that 
these T-ALL arise from one precursor cell that undergoes mutations of Notch1. However, how 
these mutations lead to the generation of T-ALL is unclear. As the NT1 mutations are RAG 
mediated, and pLCK Cre transgene activation is required for Rasa1 and Nf1 deletion, the T-ALL 
precursor population must be within the late DN2/early DN3 to DP thymocyte populations.  
 Analysis of these populations for aberrant Ras signaling showed no differences in 
strength or duration of signal compared to wild type littermate controls.  This could be due to the 
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level of detection possible from phospho-flow cytometry, or that the subset of cells with 
overactive Ras signaling is so small that it would be lost within the subpopulations analyzed. In 
an attempt to address this, thymocyte populations were subjected to apoptotic stresses, in an 
attempt to identify populations where Ras activation suppresses apoptosis. Again, no significant 
differences were found between pLCK-DKO and wild type littermate control cell survival. 
Further work into identifying the precursor population entails screening thymocyte populations 
for NT1 mutations, to determine if there is a difference in the rate of occurrence in pLCK-DKO 
and wild type cells, and if so, if this is thymocyte population specific. 
 As there does not appear to be aberrant Ras activation prior to Notch1 mutations, freshly 
isolated T-ALL cells were analyzed using phospho-flow cytometry on activated forms of Ras 
downstream effectors.  Interestingly, there was a slight but consistent increase in the strength of 
Ras signaling through both MAPK and PI3K pathways in these cells compared to littermate 
controls. However, further work in cell lines generated from pLCK-DKO T-ALL results in 
variable levels of Ras signaling both at basal levels and after stimulation, whether analyzed by 
phosphor-flow cytometry or Western blotting. This is consistent with signaling seen in cell lines 
generated from T-ALL resulting from overexpression of the RasGEF RasGRP1, where different 
cell lines have various levels of pERK levels [94]. We propose a model where aberrant Ras 
activation works downstream of the Notch1 mutations in the formation of T-ALL. Further work 
is needed to elucidate how this signaling synergizes with activated Notch1 to result in clonal 
expansion of cells. Preliminary experiments to address T-ALL cell line sensitivity to MAPK and 
PI3K inhibitors are underway.  These experiments will also address the question of whether the 
loss of the RasGAPs is essential for maintenance of the T-ALL or just in the initiation. Inhibition 
of Ras downstream effectors, singularly or in conjunction, may impair the cell line survival or 
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proliferation to a greater extent in Ras-dependent T-ALL cell lines as compared to those with no 
involvement of Ras signaling.  
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